China Rapid Finance Limited
Annual Report 2018

Plain-text annual report

XRF SCIENTIFIC LIMITED ABN 80 107 908 314 ANNUAL FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2018           CONTENTS CHAIRMAN’S LETTER DIRECTORS’ REPORT AUDITOR’S INDEPENDENCE DECLARATION CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME CONSOLIDATED STATEMENT OF FINANCIAL POSITION CONSOLIDATED STATEMENT OF CHANGES IN EQUITY CONSOLIDATED STATEMENT OF CASH FLOWS NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DIRECTORS’ DECLARATION AUDITOR’S REPORT SHAREHOLDER INFORMATION CORPORATE DIRECTORY 3 4 17 18 19 20 21 22 53 54 58 60 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 1              FINANCIAL RESULTS SUMMARY  Sales up 13% Net Profit After Tax up 29% 24,248 2,639 20,504 21,050 21,508 1,537 1,024 794 15 16 17 18 Sales Revenue ($'000) 16 18 15 Net Profit After Tax ($'000) 17 Underlying Profit Before Tax* up 12% Earnings Per Share up 33% 3,905 2.0 3,040 2,464 2,197 1.2 0.8 0.6 15 16 17 18 Underlying Profit Before Tax ($'000) 16 18 15 Earnings Per Share (Cents) 17 * Non-IFRS financial measure. Refer to page 5 for reconciliation to net profit before tax. 2 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT     CHAIRMAN’S LETTER Dear Shareholder The last twelve months have been a period of major The Board has noted the increasing focus upon changes for the Company. They have been part of a introducing and maintaining higher standards of planned programme to consolidate our position as a corporate governance for listed public companies, major laboratory services business in both Australia both small and large which have been the subject of and overseas. Major steps are underway with the expansion of our business in Europe – mainly in Germany, Belgium, wide publicity. These will apply to XRF Scientific alongside the larger companies listed on the Australian Stock Exchange. France and the UK. A major, specific project is The staff, led by the Managing Director, Vance underway in Germany and should enhance the Stazzonelli, have done an excellent job in export returns of the business. Canada and the USA challenging circumstances during the last financial are important markets which are being and will year and the company is looking to improve returns continue to be serviced from Australia and our office to shareholders in 2018-19. in Canada. We do not anticipate being adversely affected by the spat between the USA and China over tariffs. We are a major buyer of Chinese raw material products and expect to remain so. This is my last year as a Director and Chair of the Company and I’m confident that the Board and management team will be able to expand, grow strongly and deliver improved returns to the The Company’s plant in Melbourne has been shareholders in 2018-19 and beyond. significantly upgraded and will play an ever- important part in expanding the business and improving profitability. Unfortunately, over the last twelve months, the Company’s share price has languished between 16- 22 cents per share. Measures are being implemented to improve sales and profitability. One of the aims is to form the basis for lifting the share price for the benefit of our loyal shareholders. Kenneth Baxter Chairman XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 3        FINANCIAL RESULTS SUMMARY  DIRECTORS’ REPORT Your directors present their report on the company XRF Scientific Limited and its controlled entities for the financial year ended 30 June 2018. DIRECTORS The names of the directors in office at any time during or since the end of the financial year are: Kenneth Baxter (Chairman) David Brown David Kiggins Fred Grimwade Vance Stazzonelli (since 22 February 2018) Directors have been in office since the start of the financial year to the date of this report unless otherwise stated. PRINCIPAL ACTIVITY The principal activity of the economic entity during the financial year was the business of manufacturing and marketing precious metal products, specialised chemicals and instruments for the scientific, analytical and mining industries. No significant change in the nature of these activities occurred during the year. DIVIDENDS – XRF SCIENTIFIC LIMITED AND CONTROLLED ENTITIES Dividends paid to members during the financial year were as follows: Final dividend for the year 2018 $ 2017 $ 321,181 401,476 In addition to the above dividends, since the end of the financial year the directors have declared the payment of a fully franked final dividend of 0.3 cents per share to be paid on 19 October 2018 out of retained earnings at 30 June 2018. 4 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT     DIRECTORS’ REPORT REVIEW OF OPERATIONS A review of the operations of the economic entity during the financial year and the results of those operations found that, during the year, the economic entity continued to engage in its principal activity and the results and financial position are disclosed in the attached financial statements. The consolidated entity has produced a Net Profit After Tax (NPAT) of $1,024,007 for the year ended 30 June 2018, compared with $793,851 for the previous year. Details of the results for the financial year ended 30 June 2018 are as follows: Total revenue and other income NPAT Basic earnings per share – (cents per share) Diluted earnings per share – (cents per share) Underlying profit before tax 1 Increase / (decrease) June 2018 June 2017 over prior year $ $ 24,304,543 21,508,891 1,024,007 793,851 0.8 0.8 0.6 0.6 2,463,669 2,196,581 % 13 29 33 33 12 1 Non-IFRS financial information. Normalised for unusual amounts recorded in the P&L. Refer below for details: Profit before tax Acquisition related costs Precious metals factory relocation expenses Precious metals division expansion costs Research and development costs expensed June 2018 June 2017 $ 1,502,092 217,730 - 743,847 - $ 968,429 113,167 162,339 841,335 111,311 Underlying profit before tax 2,463,669 2,196,581 OPERATING RESULTS XRF Scientific Ltd (“XRF” or “Company”) is pleased to report its June 2018 full-year results to shareholders. The Company has generated revenue of $24.3m and Net Profit After Tax of $1,024k, which increased by 29% on FY17. Underlying profit before tax has increased by 12% on the PCP to $2,464k, before expensing costs associated with acquisitions, R & D and expansion of the Precious Metals Division. Acquisition-related costs were $218k during the year, compared to $113k in the PCP, which related to the acquisition and integration of Scancia into the group, including the factory closure in Canada and the cost of relocating production to Perth. The Board has determined to maintain the dividend payout ratio for the year at approximately 40% of NPAT, declaring a final fully franked dividend of 0.3 cents per share. In general, activity in the second half was slower than the first, which was mainly linked to a lower level of mining exploration activity, as reflected in lower Consumable product sales. Looking forward to FY19 we are expecting a significant improvement to results. Activity in July has been strong, and we are maintaining a good sales order book for long lead-time production items. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 5                  DIRECTORS’ REPORT OPERATING RESULTS continued The Company’s cash position was $0.4m as at 30 June 2018 and has improved to $0.6m as at 31 July 2018. Short- term borrowings have increased from $54k as at 30 June 2017 to $1.4m as at 30 June 2018. This is mainly due to the reclassification of the $1.1m building loan for the Company’s precious metals factory in Melbourne, which had an initial three-year term, and will now be renegotiated prior to the expiry in November 2018. Debt increased during the year due to the finalisation of a $1.2m purchase of equipment for the precious metals factory, which was commissioned in late November 2017. $0.5m of this loan value was to refund the Company for a deposit paid to the supplier in FY17. The new equipment significantly expands our precious metals fabrication capabilities, into product areas not previously accessible. The Consumables Division experienced a 9% increase in sales activity, with revenue of $7.5m and profit before tax of $1.6m for the year. Revenue in the 2H was $3.4m vs $4.1m in 1H, with June being slower than previous years, which can typically be a busy month as customers in Australia close their operating budgets. However, activity in July has already started very strongly, with $1m in sales invoiced for the month, which is at record levels. The demand is being generated from mining customers globally, across a range of commodities. During the last year, lithium prices remained relatively stable, as did production costs for our consumable products. The Scancia flux factory in Quebec was closed in October 2017 and the equipment was shipped to the division’s main factory in Perth. The production plant was recommissioned during the second half and is now in full-scale production. It is expected that the new micro-beads flux product offering will allow XRF to expand its market share in FY19. The Capital Equipment Division improved again during the second half, delivering a profit before tax of $181k for the year, as opposed to $70k in the PCP. The main driver of this improvement has been the strong level of electric fusion machine orders, which are manufactured in the Perth factory. Results are expected to improve strongly in FY19, as the factory in Perth is maintaining an order book of more than three months for electric fusion machines. The launch of the “xrFuse 1” one-position fusion machine has been highly successful, with numerous units already sold. The machine is a good sample preparation partner for smaller benchtop x-ray spectrometers, which are increasing in popularity. The sale of gas fusion machines is continually improving, with a good order book now being maintained. In late November, a new machine, the “Phoenix GO” was launched. Advances in our R & D program have allowed for this new product to be released, which uses gas only, without the need for oxygen or compressed air for operation. The machine is aimed at the lower pricing end of the market, and is ideally suited for cost-conscious users, with savings available both on the initial infrastructure and ongoing operating costs. Sales are progressing well, with machines sold into Europe, South America and Southern Africa. The Precious Metals Division delivered a profit before tax of $56k for the year, as compared to a loss of $575k in the PCP, which includes the result for the Germany office. The significant turnaround in results was due to increased sales activity, and non-recurring relocation costs of the precious metals factory that were in the PCP. The factory in Melbourne has been extremely busy, expanding its product portfolio and capabilities, in line with the sales activity occurring in Germany. New products are being developed both for the traditional labware portfolio and precision customised platinum products. Sales development at our office in Germany is progressing well, which achieved $1.86m of revenue during the year as compared to $609k last year. The office is still in a loss position, which amounted to $743k for the year, compared to $841k for last year. The size of the loss was increased due to forex differences caused by the strength of the Euro against the AUD, which was on average 5.7% stronger during the year. Offsetting against this loss is $232k in gross profits that were made by other parts of the group, as a result of sales made directly by the Germany office and new customers introduced to other parts of the group. 6 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT             DIRECTORS’ REPORT OPERATING RESULTS continued Our current expectation is still that the office will be breaking even on a monthly basis within this calendar year. XRF’s precision products are experiencing a strong level of acceptance in the European markets, with the first order for an aerospace customer delivered in November. Late in FY18, our margins started to expand, with new significant customers being acquired in the Labware and Glass industry markets. July was its best performance yet with revenue of EUR 102k and its monthly loss reduced to EUR 28k (unaudited), compared to the average of EUR 43k in FY18. MATTERS SUBSEQUENT TO THE END OF THE FINANCIAL YEAR A final dividend of 0.3 cents per share fully franked was declared on 28 August 2018, bringing the total dividend for the year to 0.3 cents per share fully franked (FY17: 0.24 cents per share fully franked), with a record date of 5 October 2018 and payment date of 19 October 2018. There were no other events subsequent to the reporting date which have significantly affected or may significantly affect the XRF Scientific Limited operations, results or state of affairs in future years. LIKELY DEVELOPMENTS AND EXPECTED RESULTS OF OPERATIONS Likely results in the operations of the economic entity and the expected results of those operations in the future financial year have not been included in this report, as the disclosure of such information may lead to commercial prejudice to the economic entity. SIGNIFICANT CHANGES IN STATE OF AFFAIRS There have been no significant changes in the affairs of the Group. ENVIRONMENTAL REGULATION All companies within the Group continued to comply with all environmental requirements. Wherever possible, carbon emissions have been limited, and new production techniques adopted to reduce energy use. The Directors have considered compliance with the National Greenhouse and Energy Reporting Act 2007 which requires entities to report greenhouse gas emissions and energy use. For the measurement period 1 July 2017 to 30 June 2018 the directors have assessed that there are no current reporting requirements, but the Company may be required to do so in the future. The economic entity is also subject to the environmental regulations under the laws of the Commonwealth or of a State or Territory in which it operates. The Directors are not aware of any breaches of these regulations. CORPORATE GOVERNANCE DISCLOSURE The Group’s Corporate Governance Statement for the year ended 30 June 2018 can be found at:  http://www.xrfscientific.com/corporate-governance/ The statement also summarises the extent to which the Group has complied with the Corporate Governance Council’s recommendations. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 7                  DIRECTORS’ REPORT INFORMATION ON DIRECTORS Kenneth Baxter Date of appointment: Qualifications: Chairman (Non-Executive) 5 July 2005 (13 years) Bachelor of Economics, Fellow of Australian Institute of Management and Fellow of the Australian Institute of Company Directors Experience: Part time Commissioner with the Australian Government Productivity Commission; former Chairman of PNG Energy Developments Ltd, TFG International Pty Ltd, and the Australian Dairy Corporation & Thai Dairy Industries Ltd; former Director of the Hydro Electric Corporation of Tasmania, and Air Niugini Ltd; former Secretary of Department of Premier Other current directorships: Private companies only & Cabinet Victoria Former directorships in last 3 years: Chairman of PNG Sustainable Infrastructure Ltd and Infraco Asia Developments Pte Ltd; Director of Dairy NSW and other private companies Special responsibilities: Chairman of the Board, member of the Audit & Governance and Remuneration Committees No. of shares: David Brown 1,215,623 fully paid ordinary shares Director (Non-Executive) Date of appointment: 7 June 2004 (14 years) Qualifications: Experience: Bachelor of Science, Bachelor of Economics Has over 40 years of experience in research and development and manufacturing of X-Ray Flux chemicals. Formerly Chief Chemist for Swan Brewery Co. Ltd and Chairman of Scientific Industries Council of WA. Other current directorships: Private companies only Former directorships in last 3 years: Private companies only Special responsibilities: Technical consultant to XRF Chemicals Pty Ltd No. of shares: David Kiggins 8,670,894 fully paid ordinary shares Director (Non-Executive) Date of appointment: 1 May 2012 (6 years) Qualifications: Bachelor of Science (Hons), member of the Institute of Chartered Accountants of England Experience: Ten years at Arthur Andersen, working in audit and business consulting in the UK, and Wales, member of the Institute of Chartered Secretaries and Administrators, and member of Australian Institute of Company Directors Australia, Africa and the Middle East. Formerly GM Business Development and Company Secretary at Automotive Holdings Group Ltd; Finance Director and Company Secretary at Global Construction Services Ltd. Currently the Chief Financial Officer at Heliwest. Other current directorships: Private companies only Former directorships in last 3 years: Private companies only Special responsibilities: Chairman of the Audit & Governance Committee, member of the Remuneration Committee No. of shares: 212,900 fully paid ordinary shares Fred Grimwade Date of appointment: Qualifications: Director (Non-Executive) 1 May 2012 (6 years) Bachelor of Commerce and Law, Master of Business Administration, Fellow of the Governance Institute of Australia, Fellow of the Australian Institute of Company Directors, and Life Member of the Financial Services Institute of Australasia Experience: Has held general management positions at Colonial Agricultural Company, the Colonial Group, Western Mining Corporation and Goldman, Sachs & Co. Currently a Principal and Executive Director of Fawkner Capital. Other current directorships: Chairman of CPT Global Ltd; Non-Executive Director of Select Harvests Ltd, Australian United Investment Company Ltd and other private companies Former directorships in last 3 years: Chairman of Troy Resources Ltd; Non-Executive Director of NewSat Ltd and other private companies Special responsibilities: Chairman of the Remuneration Committee, member of the Audit & Governance Committee No. of shares: 400,000 fully paid ordinary shares 8 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT             DIRECTORS’ REPORT INFORMATION ON DIRECTORS continued Vance Stazzonelli Date of appointment: Qualifications: Experience: Managing Director 22 February 2018 (6 months) Bachelor of Commerce (Professional Accounting) Vance joined XRF Scientific as Chief Financial Officer in October 2009. He was subsequently appointed to Chief Operating Officer in January 2011 and then Chief Executive Officer in August 2012. On 22 February 2018, he was appointed as Managing Director. Other current directorships: Private companies only Former directorships in last 3 years: Private companies only Special responsibilities: N/A No. of shares: 450,000 fully paid ordinary shares COMPANY SECRETARIES Vance Stazzonelli, B.Comm, CPA – Vance has held the role of Company Secretary since June 2008. Andrew Watson, B.Comm, CA – Andrew was appointed Joint Company Secretary in August 2013. OTHER KEY MANAGEMENT Andrew Watson (Chief Financial Officer – XRF Scientific Limited) Andrew joined XRF Scientific as Group Accountant in August 2012 and was promoted to Chief Financial Officer in July 2014. He is a member of the Chartered Accountants Australia and New Zealand and holds a Graduate Diploma of Applied Corporate Governance. MEETINGS OF DIRECTORS The number of meetings held by the Board of Directors including meetings of the committees of the Board and the number of meetings attended by each of the Directors during the financial year ended 30 June 2018 were as follows: Kenneth Baxter David Brown David Kiggins Fred Grimwade Vance Stazzonelli * Full meetings of Directors Meetings of committees - Audit & Governance, Remuneration A 13 13 13 13 4 B 13 13 13 13 4 A 3 ** 3 3 ** B 3 ** 3 3 ** A = Meetings held during the time the director held office or was a member of the Committee during the year. B = Meetings attended. * = Attended 4 meetings as Managing Director after appointment on 22 February 2018. The prior 9 meetings were attended as Chief Executive Officer. ** = Not a member of the relevant Committee. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 9                  DIRECTORS’ REPORT REMUNERATION REPORT (Audited) (a) Principles used to determine the nature and amount of remuneration. Remuneration governance The Remuneration Committee is a committee of the Board. Its objective is to ensure that remuneration policies and structures are fair and competitive and aligned with the long-term interests of the company. It is primarily responsible for making recommendations to the Board on:     the over-arching executive remuneration framework operation of the incentive plans which apply to the executive team, including key performance indicators and performance hurdles remuneration levels of executive directors and other key management personnel, and non-executive director fees Non-executive directors Fees and payments to non-executive directors reflect the demands which are made on, and the responsibilities of, the directors. Non-executive directors’ fees and payments are reviewed periodically by the Board. The Chairman’s fees are determined independently to the fees of non-executive directors based on comparative roles in the external market. The Chairman is not present at any discussions relating to determination of his own remuneration. The Chairman’s remuneration is inclusive of committee fees. Non-executive directors may receive share options. Managing director On 22 February 2018, the Chief Executive Officer was appointed as Managing Director. No additional remuneration will be paid to Mr Stazzonelli as part of the appointment, and his contracted terms of employment remained unchanged. Directors’ fees The current base remuneration was last reviewed in July 2016. The maximum currently stands at $400,000 per annum and was approved by shareholders at the Annual General Meeting in November 2012. Base director fees Chairman Non-Executive Directors Committee Chairman Executive pay $87,000 $55,000 $8,000 The executive pay and reward framework has three components: 1. Base pay and benefits, including superannuation 2. Short-term performance incentives, and 3. Long-term incentives. It is Board policy to review key management annually, and adjust such compensation taking into account the manager’s performance, the performance of the entity which they manage, and the performance of the Group of companies. Where appropriate, there is a direct link between financial performance (profit or growth) to key managers’ compensation by way of bonus, which is assessed under a weighted balanced scorecard method, as set out by the Remuneration Committee at the start of each year. This method is accepted by the Board as being an appropriate incentive for encouraging key management personnel to reach targets that are in excess of budgeted growth. (i) Base Pay Executives are offered a competitive base pay that forms the fixed component of pay. Base pay for executives is reviewed annually to ensure the executive’s pay is competitive with the market. An executive’s pay is reviewed on promotion. 10 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT             DIRECTORS’ REPORT REMUNERATION REPORT (Audited) continued (ii) Benefits Executives may receive benefits including car/mileage allowance. (iii) Superannuation Retirement benefits of 9.5% of the base pay are delivered to the individual super fund of the executive’s choice. (iv) Short-term performance incentives Bonuses may be paid on the performance of the individual entity based on full year performance for the financial year. In most instances bonus payments are based on the achievement of a percentage of that year’s budget and targets/objectives being met. A short-term incentive (STI) pool is available for executives during the annual review, which is subject to caps that are in place. Using a profit target ensures variable reward is only available when value has been created for shareholders and when profit is consistent with the business plan. Specific details of key management personnel bonuses can be found under the service contracts section of this report. (v) Long-term incentives There are no specific long-term incentives in place, however the matter is currently being considered by the Remuneration Committee. (vi) Assessing performance and claw-back of remuneration The Board is currently reviewing the Executive Performance Reward Policy with regards to the following: in the event of serious misconduct or a material misstatement in the Group’s financial statements, the Board may cancel or defer remuneration and may also claw back performance-based remuneration paid in previous financial years. (b) Details of remuneration (i) Non-Executive (ii) Executive Kenneth Baxter Chairman Vance Stazzonelli Managing Director David Brown David Kiggins Non-Executive Director Andrew Watson Chief Financial Officer Non-Executive Director Fred Grimwade Non-Executive Director Fixed Remuneration The level of fixed remuneration is set as to provide base level of remuneration which is both appropriate to the position and its competitive market. Fixed remuneration is reviewed annually by the Remuneration Committee based on market rates, as well as having regard to the Company, divisional and individual performance. The fixed remuneration of other key management personnel is contained in information that follows. Variable Remuneration (Short-Term Incentive) To assist in achieving the objective of retaining a high quality executive team, the Remuneration Committee links the nature and amount of the executive emoluments to the Company’s financial and operating performance. For the Managing Director, variable remuneration is calculated based on an assessment of key performance indicators using a weighted balanced scorecard method, as set out by the Remuneration Committee at the start of each year. The maximum amount payable to the Managing Director for 2018 is $70,000. There were five categories of STI performance measure (plus a discretionary component) for the year ended 30 June 2018. Those measures were chosen to provide a balance between corporate, individual, operational, strategic, financial and behavioural aspects of performance. The weighting assigned to each of the performance measures was as follows:  Group financial performance (40%)  Leadership (10%)  Stakeholder & associated business relations (5%)  Execution of business growth strategy (20%)  Compliance and risk management (5%)  Discretionary (20%) XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 11                  DIRECTORS’ REPORT REMUNERATION REPORT (Audited) continued (b) Details of remuneration continued The Remuneration Committee considered the performance of the Managing Director against the performance measures outlined above. A range of strategic targets were met, a key business acquisition was successfully completed and internal expansion plans are on schedule. All compliance obligations were met throughout the year with no reported issues and relationships with internal and external stakeholders were well managed. However, due to the Group’s current level of financial performance, it was decided by the Remuneration Committee that no bonus would be paid to the Managing Director for the 30 June 2018 financial year. Amounts of remuneration Details of the remuneration of directors and the key management personnel (as defined in AASB 124 Related Party Disclosures) of XRF Scientific Limited are set out in the following: 2018 Non-executive directors Kenneth Baxter David Brown David Kiggins Fred Grimwade Sub-total non-executive directors Executive directors Vance Stazzonelli ** Sub-total executive directors Other key management personnel Andrew Watson Sub-total key management personnel 2017 Non-executive directors Kenneth Baxter David Brown David Kiggins Fred Grimwade Sub-total non-executive directors Other key management personnel Vance Stazzonelli Andrew Watson Sub-total key management personnel Short-term employment Long-term Post- Long Cash Cash Super- Service Termination Salary Bonuses Other annuation Leave benefits $ $ $ $ $ 79,452 50,228 57,534 57,534 244,748 262,000 262,000 159,650 159,650 666,398 - - - - - - - - - - - * 171,000 - - 7,548 4,772 5,466 5,466 171,000 23,252 - - - - 171,000 24,890 24,890 15,167 15,167 63,309 Post- - - - - - 5,342 5,342 3,036 3,036 8,378 - - - - - - - - - - Short-term employment Long-term Long Cash Cash Super- Service Termination Salary Bonuses Other annuation Leave benefits $ $ $ $ $ 79,452 50,228 57,534 57,534 244,748 254,529 155,000 409,529 654,277 - - - - - - 6,393 6,393 6,393 - * 171,000 - - 7,548 4,772 5,466 5,466 171,000 23,252 - - - 171,000 24,180 15,332 39,512 62,764 - - - - - 5,205 3,016 8,221 8,221 - - - - - - - - - Total $ 87,000 226,000 63,000 63,000 439,000 292,232 292,232 177,853 177,853 909,085 Total $ 87,000 226,000 63,000 63,000 439,000 283,914 179,741 463,655 902,655 * Technical services provided by consultancy (such as technical sales and support, analytical method development). ** Appointed as Managing Director on 22 February 2018. There were no changes to remuneration or other contracted employment terms. 12 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT             DIRECTORS’ REPORT REMUNERATION REPORT (Audited) continued (b) Details of remuneration continued Percentage of performance related compensation of total remuneration Certain executive personnel are paid performance bonuses in addition to set remuneration amounts. The Board of Directors have set these bonuses to encourage growth and profitability. Bonuses are paid as per the conditions set out in page 11. The relative proportions of remuneration that are linked to performance and those that are fixed are as follows: Executive personnel Vance Stazzonelli Andrew Watson Fixed Remuneration At risk - STI At risk - LTI 2018 2017 2018 2017 2018 2017 100% 100% 100% 96% - - - 4% – – – – Options issued as part of total remuneration No options have been issued in 2017 or 2018 as part of total remuneration. Voting and comments made at the company’s 2017 Annual General Meeting The company received validly appointed proxies of 98% of “yes” votes on its remuneration report for the 2017 financial year. The remuneration resolution was carried on a show of hands. The company did not receive any specific feedback at the AGM or throughout the year on its remuneration practices. (c) Shareholder Wealth The following is a summary of key shareholder wealth statistics for the Company over the past 5 years (listed since 2006). Dividends Declared Per Share Price Market Capitalisation EBIT $ Earnings Per Share Cents 2013/14 3,358,127 2014/15 3,477,167 2015/16 2,318,737 2016/17 982,440 2017/18 1,598,268 1.8 2.0 1.2 0.6 0.8 Share Cents 1.1 0.7 0.5 0.24 0.3 Cents $ 21 21 18 17 16 27,752,990 27,752,990 24,088,645 22,750,387 22,081,257 (d) Bonuses Each individual Key Management Personnel performance bonus was discussed and reviewed against the requirements set out on page 11. Although some of the performance criteria were met by the Managing Director, it was mutually decided that a bonus would not be paid due to the financial result. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 13                  DIRECTORS’ REPORT REMUNERATION REPORT (Audited) continued (e) Shares held by key management personnel Details of equity instruments (other than options and rights) held directly, indirectly or beneficially by key management personnel and their related parties are as follows: Name Directors of XRF Scientific Limited Kenneth Baxter David Brown David Kiggins Fred Grimwade Vance Stazzonelli Securities Trading Policy Balance at 1 On-market Balance at 30 July 2017 trades June 2018 1,215,623 8,400,000 212,900 400,000 450,000 - 270,894 - - - 1,215,623 8,670,894 212,900 400,000 450,000 The Company has adopted a policy that imposes certain restrictions on Directors and employees trading in the securities of the Company. The restrictions have been imposed to prevent trading in contravention of the insider trading provisions of the Corporations Act. Option holdings There were no options over ordinary shares in the company held during the financial year by directors of XRF Scientific Limited or other key management personnel of the Group. Dividends received by key management personnel Details of dividends received directly, indirectly or beneficially by key management personnel and their related parties are as follows: Name Directors of XRF Scientific Limited Kenneth Baxter David Brown David Kiggins Fred Grimwade Vance Stazzonelli (f) Service Agreements 2018 2017 2,917 20,160 511 960 1,080 2,012 32,898 639 1,200 1,350 Remuneration for the Managing Director and Chief Financial Officer is set out in service agreements, which are detailed below: Vance Stazzonelli, Managing Director of XRF Scientific Limited Terms of agreement – Ongoing employment contract effective 1 July 2017. Base salary is $270,000 per annum (effective 1 July 2017), plus superannuation benefits of 9.5%. Payment of a termination benefit on early termination by the Company, other than for gross misconduct, equal to six months full pay. Notice period by the employee of six months. Payment of bonuses is based on a range of strategic, financial, operational, personnel, and Board-related key performance indicators. Andrew Watson, Chief Financial Officer of XRF Scientific Limited Terms of agreement – Ongoing employment contract effective 1 July 2017. Base salary is $170,000 per annum (effective 1 July 2018), plus superannuation benefits of 9.5%. Payment of a termination benefit on early termination by the Company, other than for gross misconduct, equal to three months full pay. Notice period by the employee of three months. Payment of bonuses is based on a range of strategic, financial, operational, personnel, and Board-related key performance indicators. No other key management personnel are currently employed under service contracts. 14 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT             DIRECTORS’ REPORT REMUNERATION REPORT (Audited) continued (g) Share-based compensation There was no share-based compensation to any Director or Key Management Personnel for the years ended 30 June 2017 and 2018. The Company has not adopted an employee share option scheme. (h) Remuneration consultants No remuneration consultants were used in the years ended 30 June 2018 and 30 June 2017. (i) Other transactions with key management personnel Premises were rented from a related entity of Director David Brown during the financial year. These properties were rented on normal commercial terms and conditions, totalling $115,975 (2017: $115,169). No amounts were outstanding at the end of the year. (j) Loans to directors and executives No loans were made to directors and executives during the financial years ended 30 June 2018 and 30 June 2017. End of remuneration report (Audited). NON-AUDIT SERVICES Details of the non-audit services provided by the Company’s external auditor BDO Audit (WA) Pty Ltd and its related practices during the year ended 30 June 2018 are outlined in the following table. The Directors are satisfied that the provision of non-audit services is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001. The nature and the scope of each type of non-audit service provided means that auditor independence was not compromised. During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and non-related audit firms: BDO Audit (WA) Pty Ltd Audit and review of financial reports Taxation services Other services BDO Réviseurs d'Entreprises Soc. Civ. SCRL (Belgium) Audit and review of financial reports Taxation services BDO Canada s.r.l. (Canada) Taxation services BDO AG Wirtschaftsprüfungsgesellschaft (Germany) Taxation services BDO LLP (UK) Audit and review of financial reports Total remuneration for audit and other services Consolidated 2018 $ 2017 $ 119,201 47,146 1,224 30,791 6,611 104,858 43,790 - 25,764 10,121 16,094 3,655 - 11,797 8,609 229,676 8,949 208,934 The Board is satisfied that the auditors of the Company, BDO Audit (WA) Pty Ltd remain independent. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 15                  DIRECTORS’ REPORT OPTIONS No unissued ordinary shares of XRF Scientific Limited remain under option at the date of this report. INSURANCE OF DIRECTORS AND OFFICERS During the financial year, the company paid insurance premiums to insure the directors and officers of the company and its Australian–based controlled entities. The liabilities insured are legal costs that may be incurred in defending civil or some criminal proceedings that may be brought against the officers in their capacity as officers of entities in the Group, and any other payments arising from liabilities incurred by the officers in connection with such proceedings. This does not include such liabilities that arise from conduct involving a wilful breach of duty by the officers or the improper use by the officers of their position or of information to gain advantage for themselves or someone else or to cause detriment to the company. It is not possible to apportion the premium between amounts relating to the insurance against legal costs and those relating to other liabilities. PROCEEDINGS ON BEHALF OF OR INVOLVING THE ECONOMIC ENTITY No person has applied for leave of Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the company or intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or any part of those proceedings. No proceedings have been brought or intervened in on behalf of the company with leave of the Court under section 237 of the Corporations Act 2001. AUDITOR’S INDEPENDENCE DECLARATION A copy of the auditor’s independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 17. AUDITOR BDO Audit (WA) Pty Ltd continues in office in accordance with section 327 of the Corporations Act 2001. This report is made in accordance with a resolution of directors and signed for and on behalf of the Board by: Kenneth Baxter Chairman Perth 28 August 2018 16 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT             Tel: +61 8 6382 4600 Fax: +61 8 6382 4601 www.bdo.com.au 38 Station Street Subiaco, WA 6008 PO Box 700 West Perth WA 6872 Australia DECLARATION OF INDEPENDENCE BY GLYN O'BRIEN TO THE DIRECTORS OF XRF SCIENTIFIC LIMITED As lead auditor of XRF Scientific Limited for the year ended 30 June 2018, I declare that, to the best of my knowledge and belief, there have been: 1. No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and 2. No contraventions of any applicable code of professional conduct in relation to the audit. This declaration is in respect of XRF Scientific Limited and the entities it controlled during the period. Glyn O’Brien Director BDO Audit (WA) Pty Ltd Perth, 28 August 2018 BDO Audit (WA) Pty Ltd ABN 79 112 284 787 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO Audit (WA) Pty Ltd and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation other than for the acts or omissions of financial services licensees CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2018    Revenue from continuing operations Cost of sales Gross profit Other income Share of profit / (loss) of investments accounted for using the equity method Administration expenses Other expenses Occupancy expenses Finance costs Profit before income tax Income tax expense Profit after income tax from continuing operations attributable to equity holders of XRF Scientific Limited Other comprehensive income Items that will be classified to profit or loss Foreign currency translation differences Total comprehensive income for the year Note Consolidated 2018 $ 2017 $ 5 24,250,362 21,540,489 (14,595,450) (12,660,291) 9,654,912 8,880,198 5 7 54,181 - 36,994 (68,592) (6,423,795) (6,095,043) (961,916) (722,718) (98,572) 1,502,092 (478,085) (894,582) (844,237) (46,309) 968,429 (174,578) 1,024,007 793,851 22(a) 258,567 1,282,574 (36,250) 757,601 Total comprehensive income attributable to equity holders of XRF Scientific Limited 1,282,574 757,601 Earnings per share for the year attributable to equity holders of XRF Scientific Limited Basic earnings per share (cents per share) Diluted earnings per share (cents per share) 31 31 0.8 0.8 0.6 0.6 The above Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes. 18 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2018 CURRENT ASSETS Cash and cash equivalents Trade and other receivables Inventories Other assets Total Current Assets NON-CURRENT ASSETS Property, plant and equipment Intangible assets Deferred tax asset Total Non-Current Assets Total Assets CURRENT LIABILITIES Trade and other payables Provisions Short-term borrowings Other current liabilities Current income tax liability Total Current Liabilities NON-CURRENT LIABILITIES Long-term borrowings Deferred tax liability Provisions Total Non-Current Liabilities Total Liabilities Net Assets EQUITY Issued capital Reserves Retained profits Total Equity Note Consolidated 2018 $ 2017 $ 8 9 10 11 13 14 15 16 17 18 18 19 20 415,374 833,405 4,119,689 4,634,866 7,611,983 4,875,783 414,802 484,879 12,561,848 10,828,933 8,487,225 7,239,487 15,964,438 15,942,626 916,544 700,184 25,368,207 23,882,297 37,930,055 34,711,230 1,519,838 1,632,859 1,510,310 1,385,922 166,793 366,158 422,247 54,499 191,518 40,931 4,949,021 2,342,054 883,409 278,176 94,959 1,198,737 282,574 124,768 1,256,544 1,606,079 6,205,565 3,948,133 31,724,490 30,763,097 21 22(a) 22(b) 18,584,489 18,584,489 937,358 678,791 12,202,643 11,499,817 31,724,490 30,763,097 The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 19                CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2018 30 JUNE 2018 – CONSOLIDATED Issued Share Capital Share Option Reserve $ $ Foreign Currency Translation Reserve $ Retained Profits Total $ $ Balance at 1 July 2017 18,584,489 759,243 (80,452) 11,499,817 30,763,097 Profit for the period Other comprehensive income Total comprehensive income for the period Transactions with Equity Holders in their capacity as Equity Holders Ordinary shares issued, net of transaction costs Dividends paid - - - - - - - - - - - - - 258,567 258,567 1,024,007 - 1,024,007 1,024,007 258,567 1,282,574 - - - - (321,181) (321,181) - (321,181) (321,181) Balance at 30 June 2018 18,584,489 759,243 178,115 12,202,643 31,724,490 30 JUNE 2017 – CONSOLIDATED Issued Share Capital Share Option Reserve $ $ Foreign Currency Translation Reserve $ Retained Profits Total $ $ Balance at 1 July 2016 18,584,489 759,243 (44,202) 11,107,442 30,406,972 Profit for the year Other comprehensive income / (loss) Total comprehensive income / (loss) for the period Transactions with Equity Holders in their capacity as Equity Holders Ordinary shares issued, net of transaction costs Dividends paid - - - - - - - - - - - - - (36,250) (36,250) 793,851 - 793,851 793,851 (36,250) 757,601 - - - - (401,476) (401,476) - (401,476) (401,476) Balance at 30 June 2017 18,584,489 759,243 (80,452) 11,499,817 30,763,097 The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes. 20 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               CONSOLIDATED STATEMENT OF CASH FLOWS AS AT 30 JUNE 2018 Note Consolidated 2018 $ 2017 $ Cash flows from operating activities Receipts from customers (inclusive of GST) Payments to suppliers and employees (inclusive of GST) Payment of expenses relating to business acquisitions Finance costs Income taxes paid Interest received Net cash inflow (outflow) from operating activities 29 24,839,074 21,078,302 (23,358,770) (20,255,402) (202,730) (98,572) (373,616) 2,397 807,783 (113,167) (46,309) (537,031) 29,788 156,181 (1,701,725) (1,841,573) - (232,619) 13,616 (45,663) (322,771) 109,473 (1,920,728) (2,100,534) 18 18 1,175,000 (158,905) (321,181) 694,914 141,737 (267,276) (401,476) (527,015) 833,405 3,304,773 (418,031) (2,471,368) Cash flows from investing activities Payments for property, plant and equipment Payment for acquisition of business Payments for research and development Proceeds from sale of property, plant and equipment Net cash inflow (outflow) from investing activities Cash flows from financing activities Proceeds from borrowings Repayment of borrowings Dividends paid Net cash inflow (outflow) from financing activities Cash and cash equivalents at the beginning of the financial period Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at the end of the financial period 8 415,374 833,405 The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 21                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented. (a) Basis of preparation The financial report of XRF Scientific Limited for the year ended 30 June 2018 was authorised for issue in accordance with a resolution of the directors on 28 August 2018 and covers XRF Scientific Limited as an individual entity as well as the consolidated entity consisting of XRF Scientific Limited and its subsidiaries. These financial statements are presented in the Australian currency. XRF Scientific Limited is a company limited by shares incorporated in Australia and is a for-profit entity whose shares are publicly traded on the Australian Stock Exchange. These general purpose financial statements have been prepared in accordance with Australian Standards, other authoritative pronouncements of the Australian Accounting Standards Board, Australian Accounting Interpretations and the Corporations Act 2001. Compliance with IFRS The financial statements of XRF Scientific Limited also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board. Historical cost convention These financial statements have been prepared under the historical cost convention. Critical accounting estimates The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3. Financial statement presentation The following significant accounting policies have been adopted in the preparation and presentation of the financial report. (b) Principles of consolidation (i) Subsidiaries The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of XRF Scientific Limited (“company” or “parent company”) as at 30 June 2018 and the results of all subsidiaries for the year then ended. XRF Scientific Limited and its subsidiaries together are referred to in this report as the Group or the consolidated entity. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its investment with the entity and has the ability to affect those returns through its power to direct the activities of the entity. All controlled entities have a 30 June financial year end. The consolidated financial statements are prepared by combining the financial statements of all entities that comprise the consolidated entity, being the company (the parent company) and its subsidiaries. Consistent accounting policies are employed in the preparation and presentation of the consolidated financial statements. On acquisition, the assets, liabilities and contingent liabilities of a subsidiary are measured at their fair values at the date of acquisition. Any excess of the cost of acquisition over the fair values of the identifiable net assets acquired is recognised as goodwill. If, after reassessment, the fair values of the identifiable net assets acquired exceed the cost of acquisition, the benefit is credited to profit or loss in the period of acquisition. The consolidated financial statements include the information and results of each subsidiary from the date on which the company obtains control and until such time as the company ceases to control such entities. All intercompany balances and transactions between entities in the economic entity, including any unrealised profits or losses, have been eliminated on consolidation. Accounting policies of subsidiaries are consistent with the policies adopted by the Group. 22 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES continued (ii) Investments in associates and joint-ventures Investment in associates is accounted for using the equity method of accounting in the consolidated financial statements. Under the equity method, the investment in the associates is carried in the consolidated statement of financial position at cost plus post-acquisition changes in the Group’s share of net assets of the associate. After application of the equity method, the Group determines whether it is necessary to recognise any additional impairment loss with respect to the Group’s net investment in the associate. The Group's share of the associate post-acquisition profits or losses is recognised in the statement of profit or loss and other comprehensive income. The cumulative post-acquisition movements are adjusted against the carrying amount of the investment. When the Group's share of losses in the associate equals or exceeds its interest in the associate, including any unsecured long-term receivables and loans, the Group does not recognise further losses, unless it has incurred obligations or made payments on behalf of the associate. The reporting dates of the associate and the Group are identical and the associate’s accounting policies conform to those used by the Group for like transactions and events in similar circumstances. (iii) Changes in ownership interests When the Group ceases to have control, joint control or significant influence, any retained interest in the entity is re- measured to its fair value with the change in carrying amount recognised in profit or loss. The fair value is the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate, jointly controlled entity or financial asset. In addition, any amounts previously recognised in other comprehensive income in respect of that entity are accounted for as if the Group had directly disposed of the related assets or liabilities. This may mean that amounts previously recognised in other comprehensive income are reclassified to profit or loss. If the ownership interest in a jointly-controlled entity or an associate is reduced but joint control or significant influence is retained, only a proportionate share of the amounts previously recognised in other comprehensive income are reclassified to profit or loss where appropriate. (c) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Managing Director. (d) Foreign currency translation Functional and presentation currency The functional currency of each Group entity is measured using the currency of the primary economic environment in which that entity operates. The consolidated financial statements are presented in Australian dollars which is the parent entity’s functional and presentation currency. Transaction and balances Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the year-end exchange rate. Exchange differences arising on the translation of monetary items are recognised in the Statement of Profit or Loss and Other Comprehensive Income, except where deferred in equity as a qualifying cash flow or net investment hedge. The differences taken to equity are recognised in profit or loss on disposal of the net investment. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 23                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES continued Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction, and are recognised in the profit or loss. Group Companies The results and financial position of all the Group entities (none of which has the currency of a hyperinflationary currency economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows. Assets and liabilities for each statements of financial position presented are translated at the closing rate at the date of that statement of financial position. Income and expenses for each profit or loss item are translated at average exchange rates. All resulting exchange differences are recognised in other comprehensive income. (e) Revenue recognition Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances and amounts collected on behalf of third parties. Revenue is recognised for major business activities as follows: (i) Sale of goods Revenue is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer and the costs incurred or to be incurred in respect of the transaction can be measured reliably. Risks and rewards of ownership are considered passed to the buyer at the time of delivery of goods to the customer. (ii) Interest income Interest revenue is recognised on a proportional basis taking into account the interest rates applicable to the financial assets. (iii) Dividends Dividend revenue is recognised when the right to receive a dividend has been established. (iv) Rendering of services Revenue from rendering of services is recognised in the accounting period in which the services are rendered. (f) Income tax The income tax expense or revenue for the period is the tax payable on the current years taxable income based on the national income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates which are enacted or substantially enacted for each jurisdiction. The relevant tax rates are applied to the cumulative amounts of deductible and taxable temporary differences to measure the deferred tax asset or liability. An exception is made for certain temporary differences arising from the initial recognition of an asset or a liability. No deferred tax asset or liability is recognised in relation to these temporary differences if they arose in a transaction, other than a business combination, that at the time of the transaction did not affect either accounting profit or taxable profit or loss. Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in controlled entities where the parent is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future. Current and deferred tax balances attributable to amounts recognised directly in equity are also recognised directly in equity. 24 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES continued XRF Scientific Limited and its wholly-owned Australian controlled entities have implemented the tax consolidation legislation. The head entity, XRF Scientific Limited, and the controlled entities in the tax consolidated group account for their own deferred tax amounts. Current tax is accounted for by each subsidiary entity, which is then consolidated up into the tax consolidated group, as per the tax sharing agreement. In addition to its own share of current and deferred tax amounts, XRF Scientific Limited also recognises the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from controlled entities in the tax consolidated group. Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognised as amounts receivable from or payable to other entities in the Group. Income tax is allocated under the separate taxpayer within group approach. Details about the tax funding agreement are disclosed in note 7. (g) Leases Leases of property, plant and equipment where the entity has substantially all the risks and rewards of ownership are classified as finance leases. Finance leases are capitalised at the lease’s inception at the lower of fair value of the leased property and the present value of the minimum lease payments. The corresponding rental obligations, net of finance charges, are included in other long-term payables. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to the profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The property, plant and equipment acquired under finance leases are depreciated over the shorter of the asset’s useful life and the lease term. Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases (note 25(a)). Payments made under operating leases (net of any incentives received from the lessor) are charged to the profit or loss on a straight-line basis over the period of the lease. Lease income from operating leases is recognised in income on a straight-line basis over the lease term. (h) Business combinations The acquisition method of accounting is used to account for all business combinations, including business combinations involving entities or businesses under common control, regardless of whether equity instruments or other assets are acquired. The consideration transferred for the acquisition of a subsidiary comprises the fair values of the assets transferred, the liabilities incurred and the equity interests issued by the Group. The consideration transferred also includes the fair value of any contingent consideration arrangement and the fair value of any pre-existing equity interest in the subsidiary. Acquisition-related costs are expensed as incurred. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values at the acquisition date. On an acquisition-by-acquisition basis, the Group recognises any non-controlling interest in the acquiree either at fair value or at the non-controlling interest’s proportionate share of the acquiree’s net identifiable assets. The excess of the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over the fair value of the Group’s share of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the subsidiary acquired and the measurement of all amounts has been reviewed, the difference is recognised directly in profit or loss as a bargain purchase. Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity’s incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Amounts classified as a financial liability are subsequently re-measured to fair value with changes in fair value recognised in profit or loss. All purchase consideration is recorded at fair value at the acquisition date. Contingent payments classified as debt are subsequently re-measured through profit or loss. Acquisition-related costs are expensed as incurred. Non-controlling interests in an acquiree are recognised either at fair value or at the non-controlling interest’s proportionate share of the acquiree’s net identifiable assets. This decision is made on an acquisition-by-acquisition basis. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 25                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES continued If the Group recognises previous acquired deferred tax assets after the initial acquisition accounting is completed there will no longer be any adjustment to goodwill. As a consequence, the recognition of the deferred tax asset will increase the Group’s net profit after tax. (i) Impairment of assets Goodwill and intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash flows from other assets or groups of assets (cash- generating units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of the impairment at each reporting date. (j) Cash and cash equivalents For cash flow statement presentation purposes, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid instruments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities on the Statement of Financial Position. (k) Trade receivables Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest rate method, less provision for doubtful debts. Trade receivables are due for settlement no more than 90 days from the date of recognition. Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectable are written off to the Statement of Profit or Loss and Other Comprehensive Income. A provision for impairment of receivables is established when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of receivables. Another indicator that determines the trade receivable is impaired is if the party is deemed to be bankrupt. The amount of the provision is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. Cash flows relating to short-term receivables are not discounted if the effect of discounting is immaterial. The movement in the provision is recognised in the Statement of Profit or Loss and Other Comprehensive Income. (l) Inventories Raw materials and stores, work in progress and finished goods Raw materials and stores, work in progress and finished goods are stated at the lower of cost and net realisable value. Cost comprises of direct materials, direct labour and an appropriate proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. (m) Investments and other financial assets Classification The Company classifies its investments in the following categories: other financial assets, loans and receivables. The classification depends on the purpose for which the investments were acquired. Management determines the classification of its investments at initial recognition. 26 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES continued (i) Loans and receivables Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They arise when the Company provides money, goods or services directly to a debtor with no intention of selling the receivable. They are included in current assets, except for those with maturities greater than 12 months after the reporting date which are classified as non-current assets. Loans and receivables are included in receivables in the Statement of Financial Position (note 9). (ii) Recognition and derecognition Regular purchases and sales of investments are recognised on trade-date – the date on which the Company commits to purchase or sell the asset. Investments are initially recognised at fair value plus transaction costs for all financial assets not carried at fair value through profit or loss. Financial assets are derecognised when the rights to receive the cash flows from the financial assets have expired or have been transferred and the Company has transferred substantially all the risks and rewards of ownership. (iii) Subsequent measurement Loans and receivables are carried at amortised cost using the effective interest method. Changes in the fair value of monetary securities denominated in a foreign currency and classified as available-for-sale are analysed between translation differences resulting from changes in amortised cost of the security and other changes in the carrying amount of the security. The translation differences are recognised in profit or loss and other changes in carrying amount are recognised in equity. Changes in the fair value of other monetary and non-monetary securities classified as available-for-sale are recognised in equity. When securities classified as available-for-sale are sold or impaired, the accumulated fair value adjustments recognised in equity are included in the Statement of Profit or Loss and Other Comprehensive Income as gains and losses from investment securities. Details of how the fair value of financial instruments is determined is discussed in note 2. (iv) Fair value The fair value of quoted investments are based on current bid prices. If the market for a financial asset is not active (or for unlisted securities), the Company establishes fair value by using valuation techniques. These include the use of recent arm’s length transactions, reference to other instruments that are substantially the same, discounted cash flow analysis, and option pricing models making maximum use of market inputs and relying as little as possible on entity-specific inputs. (v) Impairment The Company assesses at each reporting date whether there is objective evidence that a financial asset or group of financial assets is impaired. If there is evidence of impairment for any of the Group’s financial assets carried at amortised cost, the loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows, excluding future credit losses that have not been incurred. The cash flows are discounted at the financial asset’s original effective interest rate. The loss is recognised in the profit or loss. (n) Fair value estimation The fair value of financial assets and financial liabilities must be estimated for recognition and measurement or for disclosure purposes. The carrying amount less impairment provision of trade receivables and payables are assumed to approximate their fair values. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Company for similar financial instruments. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 27                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES continued (o) Property, plant and equipment Property, plant and equipment is stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred. Depreciation is calculated using a mixture of the straight line and diminishing value methods to allocate their cost, net of their residual values, over their estimated useful lives, as follows: Plant and Equipment Property Improvements Motor Vehicles Office Equipment 2%-40% 4%-25% 15%-25% 5%-66.67% The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting date. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount (note 1(i)). Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in the profit or loss. (p) Intangible assets (i) Goodwill Goodwill represents the excess of the cost of an acquisition over the fair value of the Company’s share of the net identifiable assets of the acquired subsidiary/associate/business at the date of acquisition. Goodwill on acquisitions of subsidiaries and businesses is included in intangible assets. Goodwill on acquisitions of associates is included in investments in associates. Goodwill is not amortised. Instead, goodwill is tested for impairment annually or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses. Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold. For the purpose of impairment testing, goodwill is allocated to the consolidated entity’s cash generating units identified according to business and geographical segments (note 14(a)). (ii) Patents, trademarks and licences Patents, trademarks and licences have a finite useful life and are carried at cost less accumulated amortisation and impairment losses. Amortisation is calculated using the straight-line method to allocate the cost of patents, trademarks and licences over their estimated useful lives, which vary from 3 to 20 years. (iii) Research and development Research expenditure is recognised as an expense as incurred. Costs incurred on development projects (relating to the design and testing of new or improved products) are recognised as intangible assets when it is probable that the project will be a success considering its commercial and technical feasibility and its costs can be measured reliably. The expenditure capitalised comprises all directly attributable costs, including costs of materials, services, direct labour and an appropriate proportion of overheads. Other development expenditures that do not meet these criteria are recognised as an expense as incurred. Development costs previously recognised as an expense are not recognised as an asset in a subsequent period. Capitalised development costs are recorded as intangible assets and amortised from the point at which the asset is ready for use on a straight-line basis over its useful life, which varies from 1 to 4 years. (iv) Customer lists The customer lists were acquired as part of a business combination. They are recognised at their fair value at the date of acquisition and subsequently amortised on a straight-line basis over the estimated useful lives, between 3 to 5 years. (q) Trade and other payables These amounts represent liabilities for goods and services provided to the Company prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 60 days of recognition. 28 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES continued (r) Borrowings Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in profit or loss over the period of the borrowings using the effective interest method. Fees paid on the establishment of loan facilities, which are not incremental costs relating to the actual draw-down of the facility, are recognised as prepayments and amortised on a straight-line basis over the term of the facility. Borrowings are removed from the Statement of Financial Position when the obligation specified in the contract is discharged, cancelled or expired. The difference between the carrying amount of a financial liability that has been extinguished or transferred to another party and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognised in other income or other expenses. Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. (s) Borrowing costs Borrowing costs incurred for the construction of any qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use or sale. All other borrowing costs are recognised as an expense in profit or loss in the period in which they are incurred. (t) Provisions Provisions are measured at the present value of management’s best estimate of the expenditure required to settle the present obligation at the reporting date. The discount rate used to determine the present value reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the provision due to the passage of time is recognised as an interest expense. Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small. Provisions for legal claims, service warranties and make good obligations are recognised when the Group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation and the amount has been reliably estimated. (u) Employee benefits (i) Short-term obligations Liabilities for wages and salaries, including non-monetary benefits and annual leave expected to be settled wholly within 12 months of the reporting date are recognised in other payables in respect of employees’ services up to the reporting date and are measured at the amounts expected to be paid when the liabilities are settled. (ii) Other long-term employee benefit obligations The liability for long service leave is recognised in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experiences of employee departures and periods of service. There amounts are not expected to be settled wholly within 12 months of the reporting date. Expected future payments are discounted using market yields at the reporting date on corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. (iii) Retirement benefit obligations The amount charged to profit or loss in respect of superannuation represents the contributions made by the Group to superannuation funds as nominated by the individual employee. Contributions made by the Company to employee superannuation funds are charged as expenses when incurred. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 29                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES continued (iv) Termination benefits Termination benefits are payable when employment is terminated before the normal retirement date, or when an employee accepts voluntary redundancy in exchange for these benefits. The Group recognises termination benefits when it is demonstrably committed to either terminating the employment of current employees according to a detailed formal plan without possibility of withdrawal or providing termination benefits as a result of an offer made to encourage voluntary redundancy. Benefits falling due more than 12 months after reporting date are discounted to present value. (v) Contributed equity Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction from the proceeds. Incremental costs directly attributable to the issue of new shares or options for the acquisition of a business are not included in the cost of acquisition as part of the purchase consideration If the entity reacquires its own equity instruments, e.g. as the result of a share buy-back, those instruments are deducted from equity and the associated shares are cancelled. No gain or loss is recognised in the profit or loss and the consideration paid including any directly attributable incremental costs (net of income taxes) is recognised directly in equity. (w) Dividends Provision is made for the amount of any dividend declared, being appropriately authorised and no longer at the discretion of the entity, on or before the end of the financial year but not distributed at reporting date. (x) Goods and services tax Revenues, expenses and assets are recognised net of the amount of associated goods and services tax (GST), unless the GST incurred is not recoverable from the taxation authority. In this case it is recognised as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to, the taxation authority, are presented as operating cash flows. (y) Earnings per share (i) Basic earnings per share Basic earnings per share is calculated by dividing the profit attributable to equity holders of the company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year. (ii) Diluted earnings per share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. 30 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES continued (z) New accounting standards and interpretations Certain new accounting Standards and Interpretations have been published that are not mandatory for 30 June 2018 reporting periods and have not been early adopted by the Group. The Group’s assessment of the impact of these new Standards and Interpretations is set out below. In all cases the Group intends to apply these standards from the application date as indicated below. (i) AASB 15 Revenue from Contracts with Customers (effective from 1 July 2018) The AASB has issued a new standard for the recognition of revenue. This will replace AASB 118 which covers contracts for goods and services and AASB111 which covers construction contracts. The new standard is based on the principle that revenue is recognised when control of a good or service transfers to a customer, so the notion of control replaces the existing notion of risks and rewards. The standard permits a modified retrospective approach for the adoption. Under this approach entities will recognise any applicable transitional adjustments in retained earnings on the date of the initial application without restating the comparative period. Entities will only need to apply the new rules to contracts that are not completed as of the date of initial application. There will be no significant impact on the Group on the adoption of this standard. (ii) AASB 16 Leases (effective from 1 July 2019) Lessee accounting Lessees are required to recognise assets and liabilities for all leases with a term of more than 12 months, unless the underlying asset is of a low value. A lessee measures right-of-use assets similarly to other non-financial assets and lease liabilities similarly to other financial liabilities. Assets and liabilities arising from a lease are initially measured on a present value basis. The measurement includes non-cancellable lease payments, and also includes payments to be made in optional periods if the lessee is reasonably certain to exercise an option to extend the lease, or not to exercise an option to terminate the lease. AASB 16 contains disclosure requirements for leases. Lessor accounting AASB 16 substantially carries forward the lessor accounting requirements in AASB 117. Accordingly, a lessor continues to classify its leases as operating leases or finance leases, and to account for those two types of leases differently. AASB 16 also requires enhanced disclosures to be provided by lessors that will improve information disclosed about a lessor’s risk exposure, particularly to residual value risk. To the extent that the entity, as lessee, has significant operating leases outstanding at the date of initial application, 1 July 2019, right-of-use assets will be recognised for the amount of the unamortised portion of the useful life, and lease liabilities will be recognised at the present value of the outstanding lease payments. Thereafter, earnings before interest, depreciation, amortisation and tax (EBITDA) will increase because operating lease expenses currently included in EBITDA will be recognised instead as amortisation of the right-of-use asset, and interest expense on the lease liability. However, there will be an overall reduction in net profit before tax in the early years of a lease because the amortisation and interest charges will exceed the current straight-line expense incurred under AASB 117 Leases. This trend will reverse in the later years. There will be no change to the accounting treatment for short-term leases less than 12 months and leases of low value items, which will continue to be expensed on a straight-line basis. (iv) AASB 9 Financial Instruments (effective from 1 July 2018) AASB 9 addresses the classification, measurement and derecognition of financial assets and financial liabilities and introduces new rules for hedge accounting. In December 2014, the AASB made further changes to the classification and measurement rules and also introduced a new impairment model. These latest amendments now complete the financial instruments standard. There will be no significant impact on the Group on the adoption of this standard. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 31                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES continued (vi) IFRIC 23 Uncertainty over Income Tax Treatments (effective from 1 January 2019) When assessing whether a taxation authority will accept an uncertain tax treatment, entities must assume that a tax audit will be conducted, with the taxation authority having full knowledge of all relevant information when conducting the tax audit. If it is not probable that a taxation authority will accept an uncertain income tax position, the effect of the uncertainty is to be reflected in determining the income tax expense and deferred tax assets and liabilities using either the ‘most likely amount’ method or the ‘expected value’ method. The probability of being selected for a tax audit is not factored in when assessing the probability of the taxation authority accepting an uncertain tax position, or in measuring the tax balances. If it is probable that the taxation authority will accept the income tax position, income tax expense and deferred tax balances will be measured consistently with the tax treatments to be used in the income tax returns/filings. There will be no significant impact on the Group on the adoption of this standard. NOTE 2: FINANCIAL RISK MANAGEMENT The Group’s activities expose it to a variety of financial risks; market risk (including foreign exchange risk, price risk, cash flow risk, fair value risk and interest rate risk); credit risk; and liquidity risk. The Group’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial performance of the Group. Risk management is carried out by management under policies approved by the Board of Directors. Management identifies, evaluates and hedges financial risks in close co-operation with the Company’s operating units. The Board provides guidance for overall risk management and other specific areas, such as mitigating foreign exchange, interest rate and credit risks, use of financial instruments and investing excess liquidity. (a) Market risk (i) Foreign exchange risk The Group is exposed to foreign currency risk on sales, purchases and borrowings that are denominated in a currency other than the Australian Dollar. The currencies giving rise to this risk are predominantly Euros, the US Dollar, and the Canadian Dollar. Foreign currency risk arises where settlement of a trade receivable, payable or borrowings is denominated in a currency that is not the entity’s functional currency, which may result in a foreign currency gain or loss. The Group seeks to mitigate this risk by engaging in a majority of commercial transactions that are generally in AUD. The Group’s exposure to foreign currency risk at the reporting date was as follows: Trade receivables Trade payables Group sensitivity 30 June 2018 30 June 2017 CAD EUR USD CAD EUR USD 113,528 566,277 482,665 197,838 809,789 437,772 1,692 79,569 52,884 70,925 18,896 168,303 Based on the financial instruments held at 30 June 2018, had the Australian dollar strengthened / weakened by 10% (based on historical reasonableness movements) against the exchange rates in the above tables, with all other variables held constant, the Group’s post-tax profit for the year would have been $135,214 lower / $165,262 higher (2017: $149,795 lower / $183,082 higher), mainly as a result of foreign currency exchange gains/losses on translation of foreign currency denominated financial instruments as detailed in the table above. 32 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 2: FINANCIAL RISK MANAGEMENT continued (ii) Price risk As the Group does not have any investments in equities or commodities, its exposure to equities price risk and commodity price risk is minimal. While the Group uses commodities in its operations, customer commitments to market rates purchased result in the Group’s exposure to commodities price risk being immaterial. (iii) Cash flow, fair value and interest rate risk As at 30 June 2018 the Group had no variable interest rate debt, therefore consider fair value interest rate risk minimal. Group sensitivity At 30 June 2018, if interest rates had changed by -/+ 100 basis points (based upon forward treasury rates) from the year- end rates with all other variables held constant, post-tax profit for the year would have been $6,732 higher / lower (2017: $981 higher / lower), mainly as a result of higher/lower interest income from cash and cash equivalents. Cash and cash equivalent balances at 30 June 2018 would have been higher/lower by the same amount. (b) Credit risk Management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis. Credit risk arises from cash and cash equivalents, trade receivables and other receivables. For banks and financial institutions, only independently rated parties with a minimum rating of ‘A’ are accepted. The Group trades only with recognised, creditworthy third parties. In addition, receivable balances are monitored on an ongoing basis with the result that the Group’s exposure to bad debts is not significant. Counterparties without external credit ratings are in majority existing customers (<6months) with no history of defaults (Group 2). With respect to credit risk arising from the other financial assets of the Group, which comprise of cash and cash equivalents, and trade and other receivables, the Group’s exposure to credit risk arises from the default of the counter party, with a maximum exposure equal to the carrying amount of these financial assets. There are no significant concentrations of credit risk within the Group at the reporting date. The following table represents the Group’s exposure to credit risk: Cash and cash equivalents (AA- rated) Trade receivables, net of impairment provision (note 9) (Group 2) Other receivables (external parties) Consolidated 2018 $ 2017 $ 415,374 833,405 4,117,736 4,603,159 1,953 31,707 4,535,063 5,468,271 Credit risk exposure is not significantly different for any of the segments of the Group. Details of impaired trade receivables, and trade receivables overdue but not impaired can be found at note 9. An analysis of the Group’s consolidated trade receivables is as follows: Current Over 30 Over 60 Over 90 days days Days Total 2018 2,919,884 838,994 182,309 176,549 4,117,736 2017 3,161,176. 723,288 405,662 347,954. 4,638,080. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 33                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 2: FINANCIAL RISK MANAGEMENT continued (c) Liquidity risk The Group’s objective is to maintain a balance between continuity of funding and flexibility through the use of bank overdrafts, bank loans, debentures, finance leases and hire purchase contracts. The below analyses the Group’s financial liabilities into relevant maturity groupings based on the remaining period at the reporting date. The amounts disclosed in the table are the contractual undiscounted cash flows. There have been no breaches or defaults on the repayment of debt. Contractual maturities of financial liabilities Less than 6 months 6 – 12 months Between 1 and 2 years Between 2 and 5 years Over 5 years Total contractual cash flows As at 30 June 2018 $ $ $ $ $ $ Carrying Amount (assets)/ liabilities $ Non-derivatives Trade and other payables Property loan Plant & equipment loan Motor vehicle loan Plant & equipment loan Total non-derivatives As at 30 June 2017 Non-derivatives Trade and other payables Property loan Plant & equipment loan Motor vehicle loan Total non-derivatives 986,931 1,127,733 24,195 6,096 133,500 2,278,455 - - 24,195 6,096 133,500 163,791 - - 24,195 6,096 267,000 297,291 - - - - 667,500 667,500 1,168,922 19,479 24,195 6,096 1,128,692 - 19,479 24,195 6,096 49,770 - 1,127,733 48,389 12,192 1,188,314 - - 24,195 6,096 30,291 - - - - - - - - - - - 986,931 1,127,733 72,585 18,288 1,201,500 986,931 1,111,500 69,653 17,584 1,070,594 3,407,037 3,256,262 1,168,922 1,166,691 120,974 30,480 1,168,922 1,111,500 113,139 28,598 2,487,067 2,422,159 The Group had access to the following undrawn borrowing facilities at the end of the reporting period: Bank overdraft facility Bank guarantee facility Consolidated 2018 $ 2017 $ 483,713 313,245 796,958 649,677 1,459,634 2,109,311 (d) Fair value estimation The fair value bases of financial assets and financial liabilities are outlined in note 1(n). All financial assets and liabilities have carrying values that are reasonable approximates of their fair values, for the Consolidated Entity. The fair values of current and non-current borrowings are based on discounted cash flows using a current borrowing rate. They are classified as level 3 fair values in the fair value hierarchy due to the use of unobservable inputs, including own credit risk. Carrying value $2,269,330 Fair value $2,373,128 34 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 3: CRITICAL ACCOUNTING ESTIMATES AND SIGNIFICANT JUDGEMENTS Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances. The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. (a) Estimated impairment of goodwill The Group tests whether goodwill has suffered any impairment, in accordance with the accounting policy stated in note 1(p). Please refer to note 14 for the details on impairment tests performed on goodwill. (b) Capitalisation of development expenditures The Group capitalises development costs where management considers it probable that the related projects will be commercially and technically feasible and successful, in accordance with the accounting policy stated in note 1(p)(iii). (c) Tax The determination of the Group's provision for income tax as well as deferred tax assets and liabilities involves significant judgements and estimates on certain matters and transactions, for which the ultimate outcome may be uncertain. If the final outcome differs from the Group's estimates, such differences will impact the current and deferred income tax assets and liabilities in the period in which such determination is made. The Group has recognised a deferred tax asset relating to the start-up losses incurred during FY17 and FY18 by the new German division. The Group has concluded that the tax losses will be recovered against the estimated future taxable income based on the approved business plans and budgets of the German division. NOTE 4: SEGMENT INFORMATION Operating Segments – AASB 8 requires a management approach under which segment information is presented on the same basis as that used for internal reporting purposes. This is consistent to the approach used in previous periods. Operating segments are reported in a uniform manner to which is internally provided to the chief operating decision maker. The chief operating decision maker has been identified as the Managing Director. An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, including those that relate to transactions with any of the Group’s other components. Each operating segment’s results are reviewed regularly by the Managing Director to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available. The Managing Director monitors segment performance based on profit before income tax expense. Segment results that are reported to the Managing Director include results directly attributable to a segment as well as those allocated on a reasonable basis. Segment capital expenditure is the total cost incurred during the period to acquire property, plant and equipment and intangible assets other than goodwill. The consolidated entity has determined that strategic decision making is facilitated by evaluation of operations on the customer segments of Capital Equipment, Precious Metals and Consumables. For each of the strategic operating segments, the Managing Director reviews internal management reports on a monthly basis. (a) Description of segments The following summary describes the operations in each of the Group’s reportable segments: Capital Equipment Design, manufacture and service organisation, specialising in automated fusion equipment, high temperature test and production furnaces, as well as general laboratory equipment. Precious Metals Manufactures products for the laboratory and platinum alloy markets. Consumables Produces and distributes consumables, chemicals and other supplies for analytical laboratories. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 35                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 4: SEGMENT INFORMATION continued (b) Primary reporting format – business segments Segment information provided to the Managing Director for the full-year ended 30 June 2018 is as follows: Full-year ended 30 June 2018 Total segment revenue Inter segment sales Revenue from external customers Profit before income tax expense * Includes $122k of acquisition costs expensed (2017: Nil) Full-year ended 30 June 2017 Total segment revenue Inter segment sales Revenue from external customers Capital Equipment $ 7,124,324 (600,266) 6,524,058 Precious Metals Consumables $ 10,978,026 (786,643) 10,191,383 $ 7,532,596 - 7,532,596 Total $ 25,634,946 (1,386,909) 24,248,037 181,496 55,590 * 1,594,042 1,831,128 6,316,245 (298,729) 6,017,516 8,950,963 (364,930) 8,586,033 6,904,731 - 6,904,731 22,171,939 (663,659) 21,508,280 Profit before income tax expense 69,628 (575,337) 1,739,356 1,233,647 Segment assets At 30 June 2018 At 30 June 2017 Segment liabilities At 30 June 2018 At 30 June 2017 Depreciation and amortisation expense For the year ended 30 June 2018 For the year ended 30 June 2017 Capital expenditure For the year ended 30 June 2018 For the year ended 30 June 2017 7,753,463 7,667,006 1,558,208 1,559,345 282,188 263,315 170,111 122,222 17,075,483 14,133,174 8,827,815 5,723,420 317,860 291,555 1,264,934 1,431,353 Revenue from external customers – segments Unallocated revenue Revenue from external customers – total Profit before income tax expense – segments Loss incurred by parent entity Profit before income tax expense from continuing operations Total segment assets Related party loan elimination Cash and cash equivalents Deferred tax asset Other corporate assets Total assets Total segment liabilities Related party loan elimination Deferred tax liability Income tax provision Other corporate liabilities Total liabilities 36 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 22,699,132 22,098,986 624,079 1,311,026 110,926 113,688 389,832 674,620 47,528,078 43,899,166 11,010,103 8,593,791 710,974 668,558 1,824,877 2,228,195 2018 $ 2017 $ 24,248,037 21,508,280 2,325 32,209 24,250,362 21,540,489 1,831,128 (329,036) 1,502,092 47,528,078 (10,351,760) (180,558) 916,544 17,751 37,930,055 11,010,103 (5,989,707) 278,176 384,566 522,427 6,205,565 1,233,647 (265,218) 968,429 43,899,166 (10,319,290) 315,626 700,184 115,544 34,711,230 8,593,791 (5,039,819) 282,574 68,772 42,815 3,948,133               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 5: REVENUE Revenue from continuing operations Sale of goods Interest received Other income Profit on sale of non-current assets Recoveries Other revenue NOTE 6: EXPENSES Profit/(loss) before income tax includes the following specific expenses Depreciation Depreciation (included in administration expenses) Depreciation (included in cost of goods sold) Total depreciation Amortisation Patents, trademarks and acquired customer lists (included in administration expenses) Research and development (included in administration expenses) Total amortisation Other specific expenses Consolidated 2018 $ 2017 $ 24,247,966 21,508,191 2,396 32,298 24,250,362 21,540,489 1,911 1,271 50,999 54,181 1,388 24,234 11,372 36,994 Consolidated 2018 $ 2017 $ 317,055 245,749 562,804 102,806 188,977 291,783 286,685 231,885 518,570 68,601 180,356 248,957 Employee benefits expenses (included in administration expenses) Rental expense relating to operating leases (included in occupancy expenses) Acquisition of business costs (included in other expenses) 4,692,622 4,409,535 610,669 217,730 719,720 113,167 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 37                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 7: INCOME TAX EXPENSE (a) Income tax expense Current tax Deferred tax Adjustments for current tax of prior periods Income tax expense is attributed to: Profit from continuing operations Deferred income tax expense included in income tax expense comprises: Decrease (increase) in deferred tax assets (note 15) (Decrease) increase in deferred tax liabilities (note 19) (b) Numerical reconciliation of income tax expense to prima facie tax payable Profit/(loss) from continuing operations before income tax expense Tax at the Australian rate of 27.5% (2017: 30%) Tax effect of amounts which are not deductible (taxable) in calculating taxable income: Acquisition of business costs Research and development expenditure Sundry items Adjustments for current tax of prior periods Income tax expense (c) Tax consolidation legislation Consolidated 2018 $ 2017 $ 753,020 (220,758) (54,177) 478,085 589,077 (259,139) (155,360) 174,578 478,085 174,578 (216,360) (290,218) (4,398) 31,079 (220,758) (259,139) 1,502,092 1,502,092 968,429 968,429 413,075 290,529 65,319 (62,841) 116,708 532,262 33,950 (88,135) 93,594 329,938 (54,177) 478,085 (155,360) 174,578 XRF Scientific Limited and its wholly-owned Australian controlled entities elected to enter into the tax consolidation regime from 1 July 2005. The accounting policy in relation to this legislation is set out in note 1(f). The entities have entered into a tax funding agreement under which the wholly-owned entities fully compensate XRF Scientific Limited for any current tax payable assumed and are compensated by XRF Scientific Limited for any current tax receivable and deferred tax assets relating to unused tax losses or unused tax credits that are transferred to XRF Scientific Limited under the tax consolidation legislation. The funding amounts are determined by reference to the amounts recognised in the wholly-owned entities’ financial statements. The amounts receivable/payable under the tax funding agreement are due upon receipt of the funding advice from the head entity, which is issued as soon as practicable after the end of each financial year. The head entity may also require payment of interim funding amounts to assist with its obligations to pay tax installments. The funding amounts are recognised as current intercompany receivables or payables. 38 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 8: CURRENT ASSETS – CASH AND CASH EQUIVALENTS Cash at bank and on hand Deposits at call Reconciliation to cash at the end of the year Balances as above Balance per statements of cash flows (a) Cash at bank and on hand Consolidated 2018 $ 370,022 45,352 415,374 2017 $ 288,052 545,353 833,405 415,374 415,374 833,405 833,405 Cash at bank earns interest at floating rates based on daily bank deposit rates of between 0.01% to 0.60% pa (2017: 0.01% to 0.95% pa). Cash available for use is as reported above, with no restrictions applicable. (b) Deposits at call Short-term deposits are made for varying periods of between no set term and 4 months, depending on the immediate cash requirements of the company, and earn interest at the respective short-term deposit rates. Deposits at call are subject to an interest rate of 2.35% pa (2017: 2.32% to 2.7% pa). (c) Risk exposure The Group’s exposure to interest rate risk is discussed in note 2. The maximum exposure to credit risk at the reporting date is the carrying amount of each class of cash and cash equivalents mentioned above. NOTE 9: CURRENT ASSETS – TRADE AND OTHER RECEIVABLES Trade receivables Allowance for impairment of receivables Other receivables – From external parties Total trade and other receivables Past due but not impaired Up to 3 months Up to 6 months Allowance for impairment of receivables Balance at 1 July (Increase)/Decrease in allowance during the year Balance at 30 June (a) Impaired trade receivables Consolidated 2018 $ 2017 $ 4,141,059 4,638,080 (23,323) 1,953 (34,921) 31,707 4,119,689 4,634,866 1,021,303 1,128,950 176,549 347,954 1,197,852 1,476,904 (34,921) 11,598 (23,323) (26,922) (7,999) (34,921) During the 2018 financial year, the allowance for impaired receivables reduced by 11,598 (2017: $7,999 increase). This was due to the settlement of a debt which was impaired in a prior period. $7,540 was received as part of the settlement. This amount has been included as ‘other income’ in the statement of profit or loss and other comprehensive income. (b) Past due but not impaired As at 30 June 2018, trade receivables of the Group of $1,197,852 (2017: $1,476,904) were past due but not impaired. These relate to a number of independent customers for whom there is no recent history of default. The ageing analysis of these trade receivables is in note 2. The other classes within trade and other receivables do not contain impaired assets and are not past due. Based on the credit history of these classes, it is expected that these amounts will be received when due. The Group does not hold any collateral in relation to these receivables. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 39                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 9: CURRENT ASSETS – TRADE AND OTHER RECEIVABLES continued (c) Other receivables These amounts generally arise from transactions outside the usual operating activities of the Group. All other receivables are subject to the same terms as trade receivables. Those terms have been described in note 1(k). (d) Effective interest rates and credit risk Information concerning the effective interest rate and credit risk of both current and non-current receivables is set out in note 2. (e) Non-current receivables There are no non-current receivables in the current year (2017: Nil). NOTE 10: CURRENT ASSETS – INVENTORIES Raw materials and spare parts Finished goods Precious metals (general) Platinum on loan (refer to note 17) Consolidated 2018 $ 2017 $ 3,618,489 2,941,620 2,130,989 1,387,492 875,634 986,871 546,671 - 7,611,983 4,875,783 Raw materials, spare parts and finished goods have increased over the last 12 months to support production of a number of additions to the Capital Equipment division’s product range. Stock was valued at lower of cost and net realisable value on 30 June 2018 and 30 June 2017. Inventory expense Inventories recognised as expense during the year ended 30 June 2018 amounted to $9,292,003 (2017: $8,235,143). The cost of writing down inventories to net realisable value during the year ended 30 June 2018 was $nil (2017: $nil). NOTE 11: OTHER CURRENT ASSETS Deposits paid Accrued income Prepayments (insurance policies, rates and other fees) NOTE 12: INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD Opening amount Share of net profit / (loss) of investments accounted for using the equity method Conversion of investment to wholly-owned subsidiary Closing amount Consolidated 2018 $ 68,589 - 346,213 414,802 2017 $ 126,246 10,827 347,806 484,879 Consolidated 2018 $ 2017 $ 607,890 (68,592) (539,298) - - - - - 40 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 13: NON-CURRENT ASSETS – PROPERTY, PLANT AND EQUIPMENT Consolidated At 30 June 2016 Cost or fair value Accumulated depreciation Net book amount Year ended 30 June 2017 Opening net book amount Additions (via business combination) Additions (other) Foreign currency adjustment Disposals Depreciation charge Closing net book amount At 30 June 2017 Cost or fair value Accumulated depreciation Net book amount Year ended 30 June 2018 Opening net book amount Additions Foreign currency adjustment Disposals Depreciation charge Closing net book amount At 30 June 2018 Cost or fair value Accumulated depreciation Net book amount Property Plant & Equipment $ Motor Improvement Office Vehicles $ s $ Equipment $ Land & Buildings $ Total $ 5,205,492 (1,837,376) 3,368,116 183,307 (63,771) 119,536 467,549 (293,540) 174,009 825,380 (478,251) 1,823,217 8,504,945 - (2,672,938) 347,129 1,823,217 5,832,007 3,368,116 119,536 186,471 733,712 (9,366) (99,135) (271,667) 3,908,131 6,017,173 (2,109,042) 3,908,131 3,908,131 1,569,626 19,511 (49,477) (292,118) 5,155,673 7,372,355 (2,216,682) 5,155,673 - 42,923 - (10,432) (28,164) 123,863 215,798 (91,935) 123,863 123,863 64,061 0 (17,923) (32,741) 137,260 216,034 (78,774) 137,260 174,009 15,011 999,188 (1,050) (10,603) (83,676) 347,129 1,823,217 5,832,007 16,336 65,750 (945) (1,810) (135,063) - - - - - 217,818 1,841,573 (11,361) (121,980) (518,570) 1,092,879 291,397 1,823,217 7,239,487 904,711 (613,314) 1,823,217 10,430,994 - (3,191,507) 291,397 1,823,217 7,239,487 291,397 1,823,217 71,922 (558) (1,048) (139,456) 0 0 0 0 7,239,487 1,872,527 18,313 (80,298) (562,804) 8,487,225 1,148,818 222,257 1,823,217 1,533,395 (384,577) 1,148,818 536,574 (314,317) 1,823,217 11,481,575 - (2,994,350) 222,257 1,823,217 8,487,225 1,470,095 (377,216) 1,092,879 1,092,879 166,918 (640) (11,850) (98,489) All items of property, plant and equipment were recorded at cost as at 30 June 2018 and 30 June 2017. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 41                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 14: NON-CURRENT ASSETS – INTANGIBLE ASSETS Consolidated At 30 June 2016 Cost or fair value Research & Development Goodwill $ $ Patents trademarks & other rights $ Total $ 897,640 14,194,351 543,343 15,635,334 Accumulated amortisation and impairment (236,249) - (171,602) (407,851) Net book amount Year ended 30 June 2017 Opening net book amount Additions (via business combination) Additions (other) Disposals Foreign currency adjustment Amortisation charge Closing net book amount At 30 June 2017 Cost or fair value 661,391 14,194,351 371,741 15,227,483 661,391 14,194,351 - 318,825 303,171 - (553) (180,356) - - (54,802) - 783,653 14,458,374 371,741 393,404 - - 4,055 (68,601) 700,599 15,227,483 712,229 303,171 - (51,300) (248,957) 15,942,626 1,220,412 14,458,374 940,249 16,619,035 Accumulated amortisation and impairment (436,759) - (239,650) (676,409) Net book amount Year ended 30 June 2018 Opening net book amount Additions Disposals Foreign currency adjustment Amortisation charge Closing net book amount At 30 June 2018 Cost or fair value 783,653 14,458,374 700,599 15,942,626 783,653 225,750 - (1,967) (188,977) 14,458,374 700,599 15,942,626 - - - - 72,718 17,094 225,750 - 87,845 - (102,806) (291,783) 818,459 14,531,092 614,887 15,964,438 1,316,160 14,531,092 908,657 16,755,909 Accumulated amortisation and impairment (497,701) - (293,770) (791,471) Net book amount 818,459 14,531,092 614,887 15,964,438 All intangible assets were recorded at cost as at 30 June 2018 and 30 June 2017. (a) Impairment tests for goodwill Goodwill is allocated to the consolidated entity’s cash generating units (CGUs) identified according to business and geographical segments. Consumables CGU Precious Metals CGU Capital Equipment CGU European Sales Office CGU 42 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT Consolidated 2018 $ 8,621,063 3,863,684 1,650,171 396,174 2017 $ 8,613,049 3,821,660 1,650,171 373,494 14,531,092 14,458,374               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 14: NON-CURRENT ASSETS – INTANGIBLE ASSETS continued (b) Significant estimate: key assumptions used for value-in-use calculations The recoverable amount of a CGU is determined based on value-in-use calculations which require the use of assumptions. The forecast cash flows for 2019 are based on the Board-approved budget. The cash flows for 2020 to 2023 have been based on extrapolating the 2019 forecast by using growth rates. Average growth rates of 3.20% (see below) used do not exceed the long- term average growth rates for the industries in which each CGU operates. The value in use model for the Precious Metals CGU incorporates significant growth representing the forecast return on the $3.4m invested between FY16 and FY18 as part of expansion plans (excluding the $1.8m spent purchasing property). The annual growth rate is expected to be higher in the initial years following completion of the project (FY20: 52%), then normalising to 3.20% in the following years. The pre-tax discount rate of 12.62% reflects specific risks relating to the relevant CGU. Net Profit (% average annual growth rate) 3.20% * 3.2% * 3.20% 3.20% * Average growth rate excludes the forecast return from the expansion project noted above Consumables Precious Metals Equipment Office (Belgium) Capital European Sales (c) Sensitivity to change in assumptions Should the 2018 forecast cash flows for the European Sales Office CGU be 70% lower than the Board-approved forecast, this would result in a material impairment charge of $218,000 against the carrying value of goodwill. This reasonably possible change in growth rates represent reasonably possible reductions in sales quantities of consumables, precious metals and capital equipment. Management believes that no other reasonably possible changes in any of the above key assumptions would cause the carrying values to materially exceed recoverable amounts. (d) Impairment charge No impairment charges have been deemed necessary for the current period. NOTE 15: NON-CURRENT ASSETS – DEFERRED TAX ASSETS Amounts recognised directly in equity: Share issue expenses Amounts recognised in profit or loss: Employee benefits DTA recognised on FY17 and FY18 losses by German subsidiary Business acquisition expenses Depreciation of tangible assets Accruals Provisions Net deferred tax assets Movements: Opening balance at 1 July (Charged)/credited to profit or loss (note 7) Closing balance at 30 June Deferred tax assets expected to be recovered within 12 months Deferred tax assets expected to be recovered after more than 12 months Consolidated 2018 $ 2017 $ 804 1,205 301,027 444,682 76,433 28,493 48,979 16,126 915,740 916,544 700,184 216,360 916,544 222,899 693,645 916,544 291,819 264,568 31,988 29,043 66,585 14,976 698,979 700,184 409,966 290,218 700,184 218,840 481,344 700,184 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 43                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 16: CURRENT LIABILITIES – TRADE AND OTHER PAYABLES Trade payables Sundry creditors and accruals Employee benefits – annual leave (a) Consolidated 2018 $ 674,123 312,808 532,907 2017 $ 791,423 377,499 463,937 1,519,838 1,632,859 Terms and conditions of trade payables vary between suppliers, however terms of trade are generally 30 days. (a) Amounts not expected to be settled within the next 12 months The entire obligation is presented as current, since the Group does not have an unconditional right to defer settlement. However, based on past experience, the Group does not expect all employees to take the full amount of accrued leave within the next 12 months. The following amounts reflect leave that is not expected to be taken within the next 12 months: Annual leave obligations expected to be settled after 12 months (b) Foreign exchange risk exposure Information about the Group’s exposure to foreign exchange risk is provided in note 2. NOTE 17: CURRENT LIABILITIES – PROVISIONS Provision for platinum loan (a) Long service leave (b) Dividends payable to ordinary shareholders Making good of leases Other provisions Consolidated 2018 $ 2017 $ 351,719 306,198 Consolidated 2018 $ 2017 $ 986,871 414,687 78,321 15,000 15,431 - 330,855 76,392 15,000 - 1,510,310 422,247 (a) Provision for platinum loan In October 2017, XRF borrowed $386,383 of platinum metal, which is inventoried to facilitate manufacturing processes and reduce lead times. The loan facility matures after 12 months and interest is calculated at market rates and payable annually. In January 2018, an additional $600,488 was borrowed, increasing the total borrowed metal to $986,871. The second loan facility matures after 12 months and interest is calculated at market rates and payable annually. At maturity, both facilities will be renewed for additional terms or the platinum will be returned. These liabilities are offset by an inventory asset of $986,871. (b) Amounts not expected to be settled within the next 12 months The current provision for long service leave includes all unconditional entitlements where employees have completed the required period of service and also those where employees are entitled to pro-rata payments in certain circumstances. The entire amount is presented as current, since the Group does not have an unconditional right to defer settlement. Based on past experience, the Group does not expect all employees to take the full amount of accrued long service leave or require payment within the next 12 months. The following amounts reflect leave that is not to be expected to be paid within the next 12 months: Long service leave obligations expected to be settled after 12 months 311,015 248,141 Consolidated 2018 $ 2017 $ 44 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 18: CURRENT & NON-CURRENT LIABILITIES – LONG-TERM BORROWINGS Property loan 1 Plant & equipment loan 2 Motor vehicle loan 3 Plant & equipment loan4 Consolidated 2018 2017 Current Non-Current Current Non-Current $ 1,111,500 45,825 11,576 217,021 1,385,922 $ - 23,828 6,008 853,573 883,409 $ $ - 1,111,500 43,486 11,013 - 69,653 17,584 - 54,499 1,198,737 1 Consists of a three-year, interest-only loan for $1,111,500, used to fund the purchase of a property in Melbourne. Interest is paid monthly, at a rate of 3.505% per annum. The lender holds a fixed and floating charge over the assets of XRF Scientific and its subsidiaries (including the property acquired) as security for the loan facility. The fair value of the loan is estimated to be $1,127,733, calculated using current market interest rates. The carrying value of the loan is $1,111,500. Covenants applicable to the loan include: maintaining a group interest cover ratio of 3x; group shareholder funds to be no less than 85% of the previous year’s closing balance; and maintaining a capital ratio of 50%. The Group has met all covenant requirements to date. 2 Consists of a three-year, interest-bearing loan for $134,042, used to fund the purchase of plant and equipment. Instalments are paid monthly (including principal and interest), at a rate of 5.25% per annum. The lender holds first registered security over the plant and equipment acquired as security for the loan facility. The fair value of the loan is estimated to be $71,879, calculated using current market interest rates. The carrying value of the loan is $69,652. No specific covenants are applicable to this loan. 3 Consists of a three-year, interest-bearing loan for $33,902, used to fund the purchase of a motor vehicle. Instalments are paid monthly (including principal and interest), at a rate of 4.99% per annum. The lender holds first registered security over the vehicle acquired as security for the loan facility. The fair value of the loan is estimated to be $18,110, calculated using current market interest rates. The carrying value of the loan is $17,584. No specific covenants are applicable to this loan. 4 Consists of a five-year, interest bearing loan for $1,175,000, used to fund the purchase of equipment. Instalments are paid monthly (including principal and interest), at a rate of 5.14% per annum. The lender holds first registered security over the equipment acquired as security for the loan facility. The fair value of the loan is estimated to be $1,155,406, calculated using current market interest rates. The carrying value of the loan is $1,070,594. No specific covenants are applicable to this loan. Net debt reconciliation Total borrowings at 1 July Borrowings acquired via business combination Proceeds from borrowings Repayment of borrowings Total borrowings at 30 June NOTE 19: NON-CURRENT LIABILITIES – DEFERRED TAX LIABILITIES Amounts recognised in profit or loss Research and development Depreciation Other Net deferred tax liabilities Movements: Opening balance at 1 July Charged/(credited) to profit or loss (note 7) Closing balance 30 June 2018 $ 2017 $ 1,253,236 1,111,500 - 1,175,000 (158,905) 2,269,331 267,275 141,737 (267,276) 1,253,236 Consolidated 2018 $ 2017 $ 245,538 19,446 13,192 278,176 282,574 (4,398) 278,176 232,445 37,581 12,548 282,574 251,495 31,079 282,574 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 45                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 20: NON-CURRENT LIABILITIES – PROVISIONS Employee benefit – long service leave NOTE 21: ISSUED CAPITAL Issued capital Ordinary shares fully paid Total issued capital Movements in ordinary share capital: Date Details 1 July 2016 Opening balance 30 June 2017 Closing balance 1 July 2017 Opening balance 30 June 2018 Closing balance (a) Ordinary shares Consolidated 2018 $ 2017 $ 94,959 124,768 Consolidated Consolidated 2018 Shares 2017 Shares 2018 $ 2017 $ 133,825,803 133,825,803 18,584,489 18,584,489 133,825,803 133,825,803 18,584,489 18,584,489 Issue Price Number of shares 133,825,803 133,825,803 133,825,803 133,825,803 $ 18,584,489 18,584,489 18,584,489 18,584,489 Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the Company in proportion to the number of and amount paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. (b) Dividend reinvestment plan The parent entity does not have a dividend reinvestment plan in place. (c) Capital risk management The Group’s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can continue to provide returns to shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt. Consolidated 2018 $ 2017 $ 2,269,331 (415,374) 1,853,957 1,253,237 (833,405) 419,832 31,724,490 30,763,097 33,578,447 31,182,929 Net debt Net debt 5.5% 1.3% The gearing ratios at 30 June 2018 and 30 June 2017 were as follows: Total borrowings Less: cash and cash equivalents Net debt / (positive cash position) Total equity Total equity plus net debt Gearing ratio 46 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 22: RESERVES AND RETAINED PROFITS (a) Reserves Foreign currency translation reserve Share-based payments reserve Balance 30 June (b) Retained Profits Movements in retained profits were as follows: Balance 1 July Net profit for the year Dividends paid or provided for Balance 30 June (c) Nature and purpose of reserves Foreign currency translation reserve Consolidated 2018 $ 2017 $ 178,115 759,243 937,358 (80,452) 759,243 678,791 11,499,817 11,107,442 1,024,007 (321,181) 793,851 (401,476) 12,202,643 11,499,817 The foreign currency translation reserve is used to recognise the unrealised gains and losses arising from the consolidation of subsidiaries denominated in currencies other than Australian dollars. Share-based payment reserve The share-based payments reserve is used to recognise the value of equity-settled share-based payments. NOTE 23: DIVIDENDS Final dividend for the prior financial year, paid in the current financial year Interim dividend for the current financial year, paid in the current financial year Total dividends provided for or paid Consolidated 2018 $ 2017 $ 321,181 401,476 - - 321,181 401,476 A fully franked dividend of 0.3 cents per share has been declared on ordinary shares post 30 June 2018. Franked Dividends Consolidated 2018 $ 2017 $ Franking credits available for subsequent financial years based on a tax rate of 27.5% (2017: 30%) 4,920,196 4,644,490 The above amounts represent the balance of the franking account as at the end of the financial year, adjusted for: (a) (b) (c) franking credits that will arise from the payment of the amount of the provision for income tax; franking debits that will arise from the payment of dividends recognised as a liability at the reporting date; and franking credits that will arise from the receipt of dividends recognised as receivables at the reporting date. The consolidated amounts include franking credits that would be available to the parent entity if distributable profits of subsidiaries were paid as dividends. The franked portions of the final dividends recommended after 30 June 2018 will be franked out of existing franking credits or out of franking credits arising from the payment of income tax in the year ended 30 June 2018. The impact on the franking account of the dividend recommended by the directors since year end, but not recognised as a liability at year end, will be a reduction in the franking account of $152,285 (2017: $137,649). XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 47                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 24: CONTINGENCIES At 30 June 2018, the consolidated entity had no material contingent liabilities in respect of claims, contingent considerations, associates and joint ventures or any other matters. NOTE 25: COMMITMENTS (a) Lease commitments Consolidated 2018 $ 2017 $ Commitments in relation to non-cancellable operating leases contracted for at the reporting date but not recognised as liabilities, payable: Within one year Later than one year but not later than five years 431,063 579,575 417,146 599,110 1,010,638 1,016,256 Operating leases have been taken out for a number of sites, office facilities and a fleet of light motor vehicles. Operating leases typically run for a period of between 3 and 5 years with an option to renew the lease after that date. Lease payments for sites and office facilities are generally increased on an annual basis in line with market related / consumer price index increases. XRF Labware Pty Ltd has lease agreements with external suppliers for the provision of 107kg of platinum, which is used for working capital purposes. The lease agreements are renewed annually and fees are paid on the current market price of platinum. The current annual agreements will expire on various dates between September 2018 and January 2019 and will be renewed accordingly. (b) Financing arrangements The Group has an overdraft facility of $1,000,000 as a safeguard on working capital requirements. An additional $1,600,000 facility is utilised for bank guarantees. The Group’s undrawn borrowing facilities were as follows as at 30 June 2018: Bank overdraft facility Bank guarantee facility Consolidated 2018 $ 483,713 313,245 796,958 2017 $ 649,677 1,459,634 2,109,311 48 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 26: REMUNERATION OF AUDITORS During the year the following fees were paid or payable for services provided by the auditor of the Company, its related practices and non-related audit firms: BDO Audit (WA) Pty Ltd Audit and review of financial reports Taxation services Other services BDO Réviseurs d'Entreprises Soc. Civ. SCRL (Belgium) Audit and review of financial reports Taxation services BDO Canada s.r.l (Canada) Taxation services BDO AG Wirtschaftsprüfungsgesellschaft (Germany) Taxation services BDO LLP (UK) Audit and review of financial reports Consolidated 2018 $ 2017 $ 119,201 47,146 1,224 30,791 6,611 104,858 43,790 - 25,764 10,121 16,094 3,655 - 11,797 8,609 229,676 8,949 208,934 NOTE 27: RELATED PARTY TRANSACTIONS (a) Parent entity The ultimate parent and controlling entity is XRF Scientific Limited which at 30 June 2018 owns 100% of all subsidiaries listed in note 28. (b) Interests in subsidiaries Interests in subsidiaries are set out in note 28. (c) Directors and key management compensation Short-term employee benefits Post-employment benefits Long-term benefits Consolidated 2018 $ 837,398 63,309 8,378 909,085 2017 $ 831,670 62,764 8,221 902,655 No other post-employment or termination benefits have been provided. Detailed remuneration disclosures are available in the remuneration report from pages 10-15. (d) Loans to key management personnel There were no loans to any key management personnel during either of the years ended 30 June 2017 or 30 June 2018. (e) Other transactions with key management personnel Premises were rented from a related entity of Director David Brown during the financial year. These properties were rented on normal commercial terms and conditions, totaling $115,975 (2017: $115,169). No amounts were outstanding at the end of the year. All directors of XRF Chemicals Pty Ltd are guarantors on a lease in Osborne Park. Vance Stazzonelli is currently the sole director. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 49                NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 28: SUBSIDIARIES The consolidated financial statements incorporate the assets, liabilities, and results of the following subsidiaries in accordance with the accounting policy described in note 1(b): Name of entity XRF Chemicals Pty Ltd XRF Labware Pty Ltd XRF Technology (WA) Pty Ltd XRF Technology (VIC) Pty Ltd XRF Scientific Americas Inc XRF Scientific Europe SPRL XRF Scientific Europe GmbH XRF Scientific UK Ltd Precious Metals Engineering (WA) Pty Ltd XFlux Pty Ltd Gestion Scancia Inc Country of Incorporation Australia Australia Australia Australia Canada Belgium Germany United Kingdom Australia Australia Canada Class of shares Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary The proportion of ownership interest is equal to the proportion of voting power held. Entity holding 2018 % 2017 % 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 NOTE 29: RECONCILIATION OF PROFIT AFTER INCOME TAX TO NET CASH FLOW PROVIDED BY OPERATING ACTIVITIES Profit for the year Depreciation and amortisation Net exchange differences Net operating assets of acquired businesses reclassified as investing activities Net (gain) loss on sale of non-current assets (Increase) decrease in trade and other debtors (Increase) decrease in inventories (Increase) decrease in other current asset (Increase) decrease in deferred tax asset (Decrease) increase in trade and other creditors (Decrease) increase in provision for income taxes (Decrease) increase in provision for deferred income tax (Decrease) increase in other liabilities (Decrease) increase in other provisions Net cash inflow from operating activities NOTE 30: SHARE-BASED PAYMENTS There were no share-based payments during the year ended 30 June 2018 (2017: Nil). Consolidated 2018 $ 1,024,007 854,587 58,007 - (2,850) 515,177 (2,736,200) 70,077 (216,360) (128,021) 325,227 (4,398) (24,725) 1,073,255 807,783 2017 $ 793,851 767,527 18,705 16,699 13,895 (601,753) (852,241) (226,476) (290,218) 523,605 (103,315) 31,079 85,408 (20,585) 156,181 50 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  FOR THE YEAR ENDED 30 JUNE 2018 NOTE 31: EARNINGS PER SHARE (a) Basic earnings per share Profit attributable to the ordinary equity holders of the company (b) Diluted earnings per share Profit attributable to the ordinary equity holders of the Company Consolidated 2018 Cents 2017 Cents 0.8 0.8 0.6 0.6 $ $ (c) Reconciliations of earnings used in calculation earnings per share Profit attributable to the ordinary equity holders of the company 1,024,007 793,851 (d) Weighted average number of shares used as the denominator Weighted average number of ordinary shares used as the denominator in calculating basic earnings per share 133,825,803 133,825,803 Number Number NOTE 32: PARENT ENTITY FINANCIAL INFORMATION (a) Summary financial information The individual financial statements for the parent entity show the following aggregate amounts: Statement of Financial Position Current assets Total assets Current liabilities Total liabilities Shareholder’s equity Issued capital Reserves Retained earnings Total comprehensive income / (loss) for the year before tax Tax benefit / (expense) Total comprehensive income / (loss) for the year after tax (b) Contingent liabilities of the parent entity The parent entity did not have any contingent liabilities as at 30 June 2018 or 30 June 2017. NOTE 33: EVENTS OCCURRING AFTER THE REPORTING DATE 2018 $ 2017 $ 8,015,499 6,343,558 21,357,808 19,724,573 12,717,756 11,012,869 13,021,474 11,314,160 18,584,489 18,584,489 1,040,077 721,275 (11,288,230) (10,895,351) 8,336,336 8,410,413 (246,036) 174,338 (71,698) (265,218) 179,627 (85,591) Dividend A final dividend of 0.3 cents per share fully franked was declared on 28 August 2018, bringing the total dividend for the year to 0.3 cents per share fully franked (FY17: 0.24 cents per share fully franked), with a record date of 5 October 2018 and payment date of 19 October 2018. Other events There were no other events subsequent to the reporting date which have significantly affected or may significantly affect the XRF Scientific Limited operations, results or state of affairs in future years. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 51                This page has been left blank intentionally. 52 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT       DIRECTORS’ DECLARATION  FOR THE YEAR ENDED 30 JUNE 2018 XRF Scientific Limited and its controlled entities ACN 107 908 314 The directors of the company declare that: 1. The financial statements, comprising the consolidated statement of profit or loss and other comprehensive income, consolidated statement of financial position, consolidated statement of cash flow, consolidated statement of changes in equity and accompanying notes, are in accordance with the Corporations Act 2001 and: (a) (b) Comply with Accounting Standards and the Corporations Regulations 2001 and other mandatory professional reporting requirements after 2001; and Give a true and fair view of the consolidated entity’s financial position as at 30 June 2018 and of its performance for the year ended on that date. 2. In the directors’ opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable. 3. The directors have been given the declarations by the Chief Executive Officer and Chief Financial Officer as required by section 295A. 4. The company has included in the notes to the financial statements an explicit and unreserved statement of compliance with International Financial Reporting Standards. This declaration is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the directors by. Kenneth Baxter Chairman Dated this 28th day of August 2018 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 53                Tel: +61 8 6382 4600 Fax: +61 8 6382 4601 www.bdo.com.au 38 Station Street Subiaco, WA 6008 PO Box 700 West Perth WA 6872 Australia INDEPENDENT AUDITOR'S REPORT To the members of XRF Scientific Limited Report on the Audit of the Financial Report Opinion We have audited the financial report of XRF Scientific Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2018, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies and the directors’ declaration. In our opinion the accompanying financial report of the Group, is in accordance with the Corporations Act 2001, including: (i) Giving a true and fair view of the Group’s financial position as at 30 June 2018 and of its financial performance for the year ended on that date; and (ii) Complying with Australian Accounting Standards and the Corporations Regulations 2001. Basis for opinion We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the Financial Report section of our report. We are independent of the Group in accordance with the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code. We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor’s report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Key audit matters Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. BDO Audit (WA) Pty Ltd ABN 79 112 284 787 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO Audit (WA) Pty Ltd and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation other than for the acts or omissions of financial services licensees Goodwill impairment assessment Key audit matter How the matter was addressed in our audit As disclosed in Note 14 of the financial report, Our procedures included, but were not limited to the goodwill represents a significant balance following: recorded in the statement of financial position. Under Australian Accounting Standards goodwill is required to be tested annually for impair ment. This was determined to be a key audit matter due to the significance of goodwill to the Group’s financial position and due to the de termination of the "Value in Use" of each cash generating unit (CGU) and whether or not an impairment charge is necessary, involving judge ments by management about the future growth rates of the business in each CGU, discount rates applied to future cash flow forecasts for each CGU and sensitivities of inputs and assumptions used in the cash flow models. (cid:127) (cid:127) (cid:127) (cid:127) (cid:127) Evaluating the Group’s categorisation of CGUs and the allocation of assets to the carrying value of CGU’s; Obtaining the group’s value in use model and agreeing amounts to a combination of board approved budgets and committed future plans; Corroborating the assumptions for the key inputs in the value in use model for the forecast revenue, costs, discount rates and terminal growth rates by comparing forecasts to historical actuals; Using our valuation specialists to assess management’s discount rate based on external data were available; Performing a sensitivity analysis on the key financial assumptions in the models. These included revenue forecasts, multipliers used in the terminal year of cash flows, and the discount rates applied; and (cid:127) Evaluating the adequacy of the related disclosures in the financial report. Other information The directors are responsible for the other information. The other information comprises the information in the Group’s annual report for the year ended 30 June 2018, but does not include the financial report and the auditor’s report thereon. Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. Responsibilities of the directors for the Financial Report The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error. In preparing the financial report, the directors are responsible for assessing the ability of the group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so. Auditor’s responsibilities for the audit of the Financial Report Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report. A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (http://www.auasb.gov.au/Home.aspx) at: http://www.auasb.gov.au/auditors_responsibilities/ar1.pdf This description forms part of our auditor’s report. Report on the Remuneration Report Opinion on the Remuneration Report We have audited the Remuneration Report included in pages 10 to 15 of the directors’ report for the year ended 30 June 2018. In our opinion, the Remuneration Report of XRF Scientific Limited, for the year ended 30 June 2018, complies with section 300A of the Corporations Act 2001. Responsibilities The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards. BDO Audit (WA) Pty Ltd Glyn O’Brien Director Perth, 28 August 2018 SHAREHOLDER INFORMATION Additional information (as at 31 July 2018) required by the ASX Listing Rules and not disclosed elsewhere in this Annual Report is set out below: SUBSTANTIAL SHAREHOLDINGS The number of shares held by substantial shareholders and their associates is as follows: Shareholder Private Portfolio Managers Skye Alba Pty Ltd Michael Karl Korber D & GD Brown Nominees Pty Ltd 1 Washington H Soul Pattinson & Co Ltd Number of Ordinary Shares2 15,563,994 13,316,641 10,017,201 8,670,894 7,910,411 1 D & GD Brown Nominees Pty Ltd is a company owned by David Brown and his wife. David Brown is a director of XRF Scientific Limited. 2 Based on information available to the Company, including substantial holding announcements released to the market. NUMBER OF OPTION HOLDERS Class of Security Nil VOTING RIGHTS Number of Holders - In accordance with the Constitution of the Company and the Corporations Act 2001 (Cth), every member present in person or by proxy at a general meeting of the members of the Company has: • On a vote taken by a show of hands, one vote; and • On a vote taken by a poll, one vote for every fully paid ordinary share held in the Company A poll may be demanded at a general meeting of the members of the Company in the manner permitted by the Corporations Act 2001 (Cth). DISTRIBUTION OF SHARE AND OPTION HOLDERS Distribution of Shares & Options 1-1,000 1,000-5,000 5,001-10,000 10,001-100,000 100,001 and above Number of Holders of Ordinary Shares Number of Holders of Options 47 89 99 314 143 692 – – – – – – 58 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT             SHAREHOLDER INFORMATION TOP 20 SHAREHOLDERS No. Holder name 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 NATIONAL NOM LTD SKYE ALBA PL KORBER, MICHAEL KARL BNP PARIBAS NOMS PL D & GD BROWN NOM PL 1 EVELIN INV PL J P MORGAN NOM AUST LTD TZELEPIS NOM PL PROSSOR, STEPHEN W + F C GREAT WESTERN CAP PL JGH METZ PL BETA GAMMA PL BROWN, DAVID + GLENYS D 1 DAVIDTS, FREDERIC BOYLES, DAVID LEROY BROWN, JEFFREY D + P N CREEL PL G & E PROPS PL IMAJ PL KLARIE PETER Number of Ordinary Shares 15,563,994 Percentage of Ordinary Shares 11.63% 13,316,641 10,017,201 7,820,000 7,000,000 6,300,000 5,342,676 3,280,000 2,669,767 2,649,578 2,000,480 2,000,000 1,670,894 1,668,706 1,500,000 1,392,977 1,230,069 1,120,000 1,000,000 890,576 9.95% 7.49% 5.84% 5.23% 4.71% 3.99% 2.45% 1.99% 1.98% 1.49% 1.49% 1.25% 1.25% 1.12% 1.04% 0.92% 0.84% 0.75% 0.67% 1 D & GD Brown Nom PL is a company owned by David Brown and his wife. David Brown is a director of XRF Scientific Limited. 88,433,559 66.08% RESTRICTED SECURITIES There are currently no restricted securities. NON-MARKETABLE PARCELS Class of Security Ordinary shares Number of Securities Number of Holders 21,948 56 UNQUOTED SECURITIES The Company does not have any unquoted securities. ON-MARKET BUY BACK The Company does not have a current on-market buy-back scheme. XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT 59              CORPORATE DIRECTORY DIRECTORS Kenneth Baxter (Non-Executive Chairman) David Brown (Non-Executive Director) David Kiggins (Non-Executive Director) Fred Grimwade (Non-Executive Director) Vance Stazzonelli (Managing Director since 22 February 2018) COMPANY SECRETARIES Vance Stazzonelli Andrew Watson KEY MANAGEMENT PERSONNEL Andrew Watson (Chief Financial Officer) REGISTERED OFFICE 86 Guthrie Street Osborne Park WA 6017 Tel: +61 8 9244 0600 Fax: +61 8 9244 9611 COMPANY AUDITOR BDO Audit (WA) Pty Ltd 38 Station Street Subiaco WA 6008 BANKERS Westpac Banking Corporation 109 St George Terrace Perth WA 6000 SOLICITORS HWL Ebsworth Level 11, Westralia Plaza 167 St Georges Terrace Perth WA 6000 SHARE REGISTRY Security Transfer Registrars 770 Canning Highway Applecross WA 6153 Tel: +61 8 9315 2333 Fax: +61 8 9315 2233 WEBSITE www.xrfscientific.com ASX Company Code: XRF 60 XRF SCIENTIFIC LIMITED | 2018 ANNUAL REPORT             

Continue reading text version or see original annual report in PDF format above